

Giuseppe Remuzzi

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5360335/publications.pdf](https://exaly.com/author-pdf/5360335/publications.pdf)

Version: 2024-02-01

1,191
papers

179,342
citations

60

172
h-index

44

385
g-index

1429
all docs

1429
docs citations

1429
times ranked

132594
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 and the spike protein in endotheliopathy. Trends in Microbiology, 2024, 32, 53-67.	7.8	15
2	Sirtuins in kidney health and disease. Nature Reviews Nephrology, 2024, 20, 313-329.	9.7	5
3	A new era in the science and care of kidney diseases. Nature Reviews Nephrology, 2024, 20, 460-472.	9.7	2
4	GFR measurement in patients with CKD: Performance and feasibility of simplified iohexol plasma clearance techniques. PLoS ONE, 2024, 19, e0306935.	2.4	0
5	Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrology Dialysis Transplantation, 2023, 38, 283-290.	0.8	18
6	Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome. International Journal of Molecular Sciences, 2023, 24, 7687.	4.2	2
7	MAFLD and glomerular hyperfiltration in subjects with prediabetes, visceral obesity and "preserved" kidney function: A cross-sectional study. Diabetes Research and Clinical Practice, 2023, 201, 110729.	2.9	3
8	A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature Medicine, 2023, 29, 1867-1876.	30.5	40
9	Rationale and design of the CV-PREVITAL study: an Italian multiple cohort randomised controlled trial investigating innovative digital strategies in primary cardiovascular prevention. BMJ Open, 2023, 13, e072040.	2.1	1
10	Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine. International Journal of Molecular Sciences, 2023, 24, 11810.	4.2	4
11	The ethics of peer review process. Updates in Surgery, 2023, 75, 1391-1392.	2.1	1
12	A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome. Journal of Clinical Investigation, 2023, 8, .	6.7	2
13	Thyroid hormone treatment counteracts cellular phenotypical remodeling in diabetic organs. IScience, 2023, 26, 107826.	4.1	1
14	Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). Journal of the American Society of Nephrology: JASN, 2023, 34, 1733-1751.	0.5	14
15	Endothelial Glycocalyx of Peritubular Capillaries in Experimental Diabetic Nephropathy: A Target of ACE Inhibitor-Induced Kidney Microvascular Protection. International Journal of Molecular Sciences, 2023, 24, 16543.	4.2	2
16	Authors' Reply: Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?. Journal of the American Society of Nephrology: JASN, 2023, 34, 2052-2053.	0.5	0
17	Excess mortality in Italy in 2020 by sex and age groups accounting for demographic changes and temporal trends in mortality. Panminerva Medica, 2022, 64, .	0.8	7
18	Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. Nephrology Dialysis Transplantation, 2022, 37, 239-254.	0.8	82

#	ARTICLE	IF	CITATIONS
19	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , 2022, 59, 309-317.	2.6	2
20	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. <i>Blood Advances</i> , 2022, 6, 866-881.	5.5	41
21	Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the <sc>VEGF</sc>/caveolin<sc>1</sc>/<sc>PV</sc><sc>1</sc> signaling pathway. <i>Journal of Pathology</i> , 2022, 256, 468-479.	4.5	23
22	Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint (PROBE) trial. <i>EClinicalMedicine</i> , 2022, 43, 101227.	7.2	18
23	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. <i>EClinicalMedicine</i> , 2022, 43, 101240.	7.2	8
24	Imaging the Kidney with an Unconventional Scanning Electron Microscopy Technique: Analysis of the Subpodocyte Space in Diabetic Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1699.	4.2	5
25	Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19. <i>Frontiers in Pharmacology</i> , 2022, 13, 842473.	3.7	6
26	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. <i>Frontiers in Immunology</i> , 2022, 13, 827146.	5.0	50
27	Primary care in a National Health Service: time for radical reform. <i>Family Practice</i> , 2022, 39, 994-995.	2.2	6
28	Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy. <i>Journal of Immunology</i> , 2022, 208, 1772-1781.	0.8	2
29	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109804.	2.9	11
30	Glomerular hyperfiltration. <i>Nature Reviews Nephrology</i> , 2022, 18, 435-451.	9.7	79
31	A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2). <i>Frontiers in Medicine</i> , 2022, 9, 785785.	2.7	18
32	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	7.1	134
33	Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome. <i>Cells</i> , 2022, 11, 1755.	4.3	3
34	Low Nephron Number Induced by Maternal Protein Restriction Is Prevented by Nicotinamide Riboside Supplementation Depending on Sirtuin 3 Activation. <i>Cells</i> , 2022, 11, 3316.	4.3	8
35	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. <i>Nature Reviews Nephrology</i> , 2021, 17, 46-64.	9.7	477
36	Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study. <i>Nephron</i> , 2021, 145, 137-149.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis. <i>Nephron</i> , 2021, 145, 428-444.	1.8	6
38	Long-term follow-up of recovered patients with COVID-19. <i>Lancet, The</i> , 2021, 397, 173-175.	12.2	95
39	Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN Oby25 trial: A multi-country feasibility study. <i>PLoS Medicine</i> , 2021, 18, e1003408.	8.5	29
40	<i>Nephrology Worldwide</i>: A Book Review. <i>Nephron</i> , 2021, 145, 212-213.	1.8	0
41	The impact of COVID-19 on total mortality in Italy up to November 2020. <i>Panminerva Medica</i> , 2021, , .	0.8	7
42	Albuminuria as a risk factor for mild cognitive impairment and dementiaâ”what is the evidence?. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii55-ii62.	0.8	17
43	Third-party bone marrowâ”derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , 2021, 21, 2795-2809.	5.0	22
44	At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. <i>Panminerva Medica</i> , 2021, 63, 51-61.	0.8	35
45	Functional outcome of displaced middle third clavicular fractures treated by plate osteosynthesis. <i>International Journal of Research in Orthopaedics</i> , 2021, 7, 335.	0.1	0
46	Bergamo and Covid-19: How the Dark Can Turn to Light. <i>Frontiers in Medicine</i> , 2021, 8, 609440.	2.7	15
47	Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 575-587.	4.6	7
48	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. <i>Lancet Oncology, The</i> , 2021, 22, 558-570.	10.2	64
49	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021, 397, 1625-1636.	12.2	495
50	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003668.	8.5	8
51	Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. <i>Stem Cell Research and Therapy</i> , 2021, 12, 332.	5.8	3
52	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. <i>Frontiers in Immunology</i> , 2021, 12, 711915.	5.0	2
53	RIDE: Theia-Based Web IDE for the Reflex Language. , 2021, , .		4
54	The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 251.	2.9	31

#	ARTICLE	IF	CITATIONS
55	CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. <i>Frontiers in Genetics</i> , 2021, 12, 670727.	2.4	12
56	A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. <i>EClinicalMedicine</i> , 2021, 37, 100941.	7.2	42
57	Insights into Glomerular Filtration and Albuminuria. <i>New England Journal of Medicine</i> , 2021, 385, 477-478.	30.7	2
58	Human iPSC-derived neural crest stem cells can produce EPO and induce erythropoiesis in anemic mice. <i>Stem Cell Research</i> , 2021, 55, 102476.	0.7	4
59	COVID-19 from a pharmacological perspective. <i>Advances in Biological Regulation</i> , 2021, 81, 100821.	2.8	0
60	Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 252-263.	2.1	7
61	Effect of open fire on dynamic compression mechanical behavior of granite under different strain rates. <i>Arabian Journal of Geosciences</i> , 2021, 14, 1.	1.4	6
62	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii14-ii23.	0.8	12
63	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.	3.2	17
64	Unravelling the Role of PAX2 Mutation in Human Focal Segmental Glomerulosclerosis. <i>Biomedicines</i> , 2021, 9, 1808.	3.3	4
65	Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis. <i>Scientific Reports</i> , 2021, 11, 23580.	3.5	12
66	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0261113.	2.4	29
67	Autotaxin Inhibitor Protects from Chronic Allograft Injury in Rat Kidney Allotransplantation. <i>Nephron</i> , 2020, 144, 38-48.	1.8	7
68	Accelerating the Depletion of Circulating Anti-Phospholipase A ₂ Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab. <i>Nephron</i> , 2020, 144, 30-35.	1.8	28
69	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. <i>Stem Cells Translational Medicine</i> , 2020, 9, 427-432.	3.6	22
70	Update on mesenchymal stromal cell studies in organ transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 27-34.	1.6	4
71	COVID-19 and lombardy: TESTING the impact of the first wave of the pandemic. <i>EBioMedicine</i> , 2020, 61, 103069.	6.1	38
72	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. <i>Immunobiology</i> , 2020, 225, 152001.	2.0	123

#	ARTICLE	IF	CITATIONS
73	Podocytopathies. <i>Nature Reviews Disease Primers</i> , 2020, 6, 68.	16.0	278
74	Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?. <i>Kidney International</i> , 2020, 98, 1084-1087.	5.6	8
75	Italy's first wave of the COVID-19 pandemic has ended: no excess mortality in May, 2020. <i>Lancet, The</i> , 2020, 396, e27-e28.	12.2	94
76	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. <i>Blood</i> , 2020, 136, 2103-2117.	1.4	96
77	Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease. <i>Cell Transplantation</i> , 2020, 29, 096368972096546.	2.6	1
78	Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. <i>Kidney Medicine</i> , 2020, 2, 804-809.	1.9	2
79	Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. <i>Frontiers in Medicine</i> , 2020, 7, 579418.	2.7	9
80	Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c+F4/80+ Macrophages through IL-1R8 Regulation. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 517-531.	0.5	19
81	Adaptations and Lessons in the Province of Bergamo. <i>New England Journal of Medicine</i> , 2020, 382, e71.	30.7	113
82	The case of complement activation in COVID-19 multiorgan impact. <i>Kidney International</i> , 2020, 98, 314-322.	5.6	287
83	Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. <i>Nephron</i> , 2020, 144, 213-221.	1.8	254
84	COVID-19 and Italy: what next?. <i>Lancet, The</i> , 2020, 395, 1225-1228.	12.2	2,473
85	Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. <i>BMJ Case Reports</i> , 2020, 13, e232896.	0.5	35
86	Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. <i>Nephron</i> , 2020, 144, 195-203.	1.8	4
87	Evaluation of Biodegradable Stent Graft Coatings in Pig and Rabbit Models. <i>Journal of Vascular Research</i> , 2020, 57, 65-75.	1.4	3
88	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 709-733.	12.2	3,341
89	Reply to the Comment by Dr. Cure on â€œShould COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockadeâ€. <i>Nephron</i> , 2020, 144, 253-254.	1.8	7
90	Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 618387.	5.0	43

#	ARTICLE	IF	CITATIONS
91	Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 618243.	5.0	19
92	Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes. <i>Scientific Reports</i> , 2020, 10, 8418.	3.5	53
93	Serum Alkaline Phosphatase Level Predicts Cardiac Valve Calcification in Maintenance Hemodialysis Patients. <i>Blood Purification</i> , 2020, 49, 550-559.	1.9	8
94	C3a receptor blockade protects podocytes from injury in diabetic nephropathy. <i>Journal of Clinical Investigation</i> , 2020, 5, .	6.7	50
95	Role of ultrastructural determinants of glomerular permeability in ultrafiltration function loss. <i>Journal of Clinical Investigation</i> , 2020, 5, .	6.7	10
96	A recurrent question from a primary care physician: How should I treat my COVID-19 patients at home?. <i>Clinical and Medical Investigations</i> , 2020, 5, .	0.3	8
97	A recurrent question from a primary care physician: How should I treat my COVID-19 patients at home? An update. <i>Clinical and Medical Investigations</i> , 2020, 5, .	0.3	6
98	Challenges in Understanding Acute Postinfectious Glomerulonephritis: Are Anti-Factor B Autoantibodies the Answer?. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 670-672.	0.5	8
99	Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. <i>Pediatric Nephrology</i> , 2019, 34, 1311-1323.	1.8	36
100	A First Step toward a New Approach to Treating Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2019, 381, 86-88.	30.7	10
101	Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?. <i>Kidney International</i> , 2019, 96, 13-15.	5.6	11
102	<i>Sirt3</i> Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by <i>Opa1</i> Gene Transfer. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 1255-1271.	5.5	80
103	More about Factor H Autoantibodies in Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2019, 381, 1590-1592.	30.7	9
104	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. <i>Frontiers in Genetics</i> , 2019, 10, 681.	2.4	11
105	Reply to "Strengths and limitations of estimated and measured GFR™". <i>Nature Reviews Nephrology</i> , 2019, 15, 785-786.	9.7	6
106	C3 glomerulopathy " understanding a rare complement-driven renal disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 129-143.	9.7	241
107	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1199-1208.	4.6	89
108	Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research. <i>American Journal of Nephrology</i> , 2019, 49, 143-145.	3.2	3

#	ARTICLE	IF	CITATIONS
109	Mesenchymal Stromal Cells for Transplant Tolerance. <i>Frontiers in Immunology</i> , 2019, 10, 1287.	5.0	55
110	Measles Virus Infection Fosters Dendritic Cell Motility in a 3D Environment to Enhance Transmission to Target Cells in the Respiratory Epithelium. <i>Frontiers in Immunology</i> , 2019, 10, 1294.	5.0	18
111	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. <i>Frontiers in Immunology</i> , 2019, 10, 853.	5.0	32
112	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	5.6	49
113	Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells. <i>Scientific Reports</i> , 2019, 9, 8001.	3.5	47
114	A preclinical overview of emerging therapeutic targets for glomerular diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 593-606.	3.4	10
115	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. <i>Kidney International</i> , 2019, 96, 906-917.	5.6	32
116	Orphan drugs – Authors' reply. <i>Lancet, The</i> , 2019, 393, 1595-1596.	12.2	0
117	CRISPR-Cas9-Mediated Correction of the G189R-PAX2 Mutation in Induced Pluripotent Stem Cells from a Patient with Focal Segmental Glomerulosclerosis. <i>CRISPR Journal</i> , 2019, 2, 108-120.	3.0	4
118	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 338-350.	2.0	17
119	An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. <i>American Journal of Kidney Diseases</i> , 2019, 74, 56-72.	2.0	77
120	Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association. <i>Nephron</i> , 2019, 142, 264-270.	1.8	2
121	Mesenchymal stromal cell-based therapy in kidney diseases and transplantation. <i>Italian Journal of Medicine</i> , 2019, 13, 3-14.	0.3	1
122	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 224-238.	2.0	46
123	Why and how did Leonardo happen: the Renaissance context. <i>Lancet, The</i> , 2019, 393, 1396-1397.	12.2	0
124	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , 2019, 16, e1002777.	8.5	47
125	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1177-1190.	4.6	16
126	Vascularized Parenchymal Mass Preserved with Partial Nephrectomy: Functional Impact and Predictive Factors. <i>European Urology Oncology</i> , 2019, 2, 97-103.	6.2	22

#	ARTICLE	IF	CITATIONS
127	Mesenchymal stromal cells in kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 40-46.	2.1	13
128	Urinary proteome signature of Renal Cysts and Diabetes syndrome in children. <i>Scientific Reports</i> , 2019, 9, 2225.	3.5	16
129	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 1121-1130.	1.1	14
130	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.	2.0	19
131	Bleeding and Hemostasis in Acute Renal Failure. , 2019, , 630-635.e2.		1
132	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 115-127.	11.0	216
133	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 128-139.	11.0	237
134	Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. <i>Microorganisms</i> , 2019, 7, 15.	3.7	24
135	Estimated GFR: time for a critical appraisal. <i>Nature Reviews Nephrology</i> , 2019, 15, 177-190.	9.7	203
136	Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. <i>International Journal of Cardiology</i> , 2019, 275, 145-151.	1.7	14
137	Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor. <i>International Journal of Cardiology</i> , 2019, 278, 243-249.	1.7	43
138	Submaximal exercise blood pressure and cardiovascular structure in adolescence. <i>International Journal of Cardiology</i> , 2019, 275, 152-157.	1.7	13
139	Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. <i>Journal of Clinical Investigation</i> , 2019, 4, .	6.7	24
140	Proteinuria and Tubulotoxicity. , 2019, , 197-214.		2
141	Acute Renal Failure in Kidney Transplant Recipients. , 2019, , 1279-1285.e3.		0
142	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. <i>Journal of Immunology</i> , 2018, 200, 2464-2478.	0.8	133
143	The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. <i>Pharmacoeconomics - Open</i> , 2018, 2, 459-467.	1.9	18
144	Invited letter in response to: "œœ the kidney donor profile index (KDPI) universal or UNOS-specific?â€ American Journal of Transplantation, 2018, 18, 1033-1034.	5.0	7

#	ARTICLE	IF	CITATIONS
145	Mesenchymal Stromal Cells for AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 7-9.	0.5	7
146	Mesenchymal stromal cells for tolerance induction in organ transplantation. <i>Human Immunology</i> , 2018, 79, 304-313.	2.6	42
147	Blood Pressure and Metabolic Effects of Acetyl-L-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. <i>Journal of the Endocrine Society</i> , 2018, 2, 420-436.	0.2	29
148	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1414-1427.	0.9	142
149	Early and late scanning electron microscopy findings in diabetic kidney disease. <i>Scientific Reports</i> , 2018, 8, 4909.	3.5	31
150	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 27-40.	11.0	25
151	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 283-294.	0.5	96
152	Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 240-249.	0.5	34
153	Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 362-375.	0.5	57
154	Physiological and pathophysiological implications of PGE2 and the PGE2 synthases in the kidney. <i>Prostaglandins and Other Lipid Mediators</i> , 2018, 134, 1-6.	2.1	17
155	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. <i>American Journal of Kidney Diseases</i> , 2018, 71, 91-101.	2.0	58
156	Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. <i>Data in Brief</i> , 2018, 21, 2075-2081.	1.1	5
157	INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i317-i317.	0.8	2
158	Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. <i>Frontiers in Immunology</i> , 2018, 9, 2329.	5.0	42
159	SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. <i>Journal of Clinical Investigation</i> , 2018, 3, .	6.7	126
160	A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases. <i>BMC Medical Research Methodology</i> , 2018, 18, 110.	3.2	2
161	Maternal and environmental risk factors for neonatal AKI and its long-term consequences. <i>Nature Reviews Nephrology</i> , 2018, 14, 688-703.	9.7	64
162	Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study. <i>Nephron</i> , 2018, 139, 313-318.	1.8	168

#	ARTICLE	IF	CITATIONS
163	Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. <i>Nephron</i> , 2018, 140, 1-8.	1.8	22
164	The role of B7-1 in proteinuria of glomerular origin. <i>Nature Reviews Nephrology</i> , 2018, 14, 589-596.	9.7	30
165	The Glomerulus: Mechanisms and Patterns of Injury. , 2018, , 189-206.		2
166	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1359.	5.0	59
167	ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. <i>Diabetes</i> , 2018, 67, 2069-2083.	0.9	9
168	Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery. <i>EBioMedicine</i> , 2018, 33, 253-268.	6.1	29
169	Toward longitudinal studies of hemodynamically induced vessel wall remodeling. <i>International Journal of Artificial Organs</i> , 2018, 41, 714-722.	1.5	17
170	Outrageous prices of orphan drugs: a call for collaboration. <i>Lancet, The</i> , 2018, 392, 791-794.	12.2	136
171	Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 299-308.	1.7	30
172	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, ii4-ii14.	0.8	99
173	Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. <i>PLoS ONE</i> , 2018, 13, e0202417.	2.4	12
174	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. <i>Stem Cell Research and Therapy</i> , 2018, 9, 220.	5.8	29
175	Disaster medicine and response: Optimizing life-saving potential. <i>American Journal of Disaster Medicine</i> , 2018, 13, 253-264.	0.3	14
176	Ethical issues in dialysis therapy. <i>Lancet, The</i> , 2017, 389, 1851-1856.	12.2	43
177	A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. <i>Lancet, The</i> , 2017, 390, 424-428.	12.2	131
178	Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response. <i>American Journal of Transplantation</i> , 2017, 17, 2312-2325.	5.0	33
179	Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients. <i>Nephron</i> , 2017, 135, 173-180.	1.8	4
180	BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. <i>American Journal of Kidney Diseases</i> , 2017, 70, 145-150.	2.0	25

#	ARTICLE	IF	CITATIONS
181	Comparison of exposure response relationship of atrasentan between North American and Asian populations. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 545-552.	4.6	4
182	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2167-2179.	0.5	205
183	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , 2017, 390, 1888-1917.	12.2	708
184	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2729-2737.	0.5	131
185	ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. <i>Current Opinion in Pharmacology</i> , 2017, 33, 34-40.	3.6	29
186	New biologics in the treatment of rare glomerular diseases of childhood. <i>Current Opinion in Pharmacology</i> , 2017, 33, 27-33.	3.6	5
187	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	12.2	511
188	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1237-1247.	4.6	152
189	Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3055-3065.	0.5	155
190	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 522-531.	2.0	16
191	MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. <i>Diabetologia</i> , 2017, 60, 1114-1125.	6.6	56
192	Child and Adolescent Health From 1990 to 2015. <i>JAMA Pediatrics</i> , 2017, 171, 573.	6.4	321
193	Tissue Engineering of Renal Tissue (Kidney)., 2017, , 575-602.		0
194	AAV9-mediated engineering of autotransplanted kidney of non-human primates. <i>Gene Therapy</i> , 2017, 24, 308-313.	4.8	0
195	Experimental Evaluation of Kidney Regeneration by Organ Scaffold Recellularization. <i>Scientific Reports</i> , 2017, 7, 43502.	3.5	54
196	Clinical use of computational modeling for surgical planning of arteriovenous fistula for hemodialysis. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 26.	3.1	14
197	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 749-753.	4.6	22
198	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2017, 92, 796-808.	5.6	42

#	ARTICLE	IF	CITATIONS
199	The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 130-137.	13.5	8
200	The Vaticanâ€“Mario Negriâ€“ Lancet Commission on the value of life. <i>Lancet, The</i> , 2017, 390, 1573.	12.2	0
201	Addressing acute kidney injury in critically ill newborn babies. <i>The Lancet Child and Adolescent Health</i> , 2017, 1, 161-163.	5.6	0
202	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. <i>Nature Communications</i> , 2017, 8, 983.	13.2	130
203	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , 2017, 17, 441-448.	2.3	6
204	Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. <i>Seminars in Nephrology</i> , 2017, 37, 447-463.	1.6	21
205	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	12.2	1,647
206	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	12.2	3,733
207	Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. <i>Scientific Reports</i> , 2017, 7, 11518.	3.5	95
208	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.	7.1	395
209	Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study. <i>American Journal of Transplantation</i> , 2017, 17, 3159-3171.	5.0	47
210	The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. <i>American Journal of Pathology</i> , 2017, 187, 2441-2450.	4.2	20
211	Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled<i>post hoc</i> analysis. <i>Transplant International</i> , 2017, 30, 1275-1283.	1.8	33
212	Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017, 46, 488-497.	3.2	8
213	Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?. <i>American Journal of Kidney Diseases</i> , 2017, 70, 754-757.	2.0	13
214	Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. <i>BMJ Global Health</i> , 2017, 2, e000453.	5.5	11
215	Kidney Transplantation, Bioengineering, and Regeneration. , 2017, , xxv.		7
216	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. <i>Journal of Immunology</i> , 2017, 199, 1021-1040.	0.8	58

#	ARTICLE	IF	CITATIONS
217	Therapeutic Plasma Exchange in Neonates and Infants: Successful Use of a Miniaturized Machine. Blood Purification, 2017, 44, 100-105.	1.9	12
218	Acute Kidney Injury and Hemolytic Anemia Secondary to <i>Mycoplasma pneumoniae</i> Infection. Nephron, 2017, 137, 148-154.	1.8	6
219	Treatment of membranous nephropathy: time for a paradigm shift. Nature Reviews Nephrology, 2017, 13, 563-579.	9.7	122
220	Achieving remission of proteinuria in childhood CKD. Pediatric Nephrology, 2017, 32, 321-330.	1.8	12
221	Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. Diabetes, 2017, 66, 75-86.	0.9	71
222	Should We Still Believe in Randomized Controlled Trials in Nephrology?. Nephron, 2017, 136, 281-286.	1.8	5
223	Epidemiology of End-Stage Renal Failure. , 2017, , 5-11.		7
224	Developmental Approaches to Kidney Regeneration. , 2017, , 1039-1050.		0
225	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2017, , 334-345.e1.		0
226	Maintenance Immunosuppression in Kidney Transplantation. , 2017, , 259-276.		0
227	Recellularization of Kidney Scaffold With Stem Cells. , 2017, , 877-886.		5
228	Commenti alla delibera. Mecosan, 2017, , 173-180.	0.1	0
229	Interplay between Diagnostic Criteria and Prognostic Accuracy in Chronic Kidney Disease. PLoS Medicine, 2016, 13, e1002129.	8.5	1
230	Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis. Nephron, 2016, 133, 129-138.	1.8	8
231	A previously unrecognized role of C3a in proteinuric progressive nephropathy. Scientific Reports, 2016, 6, 28445.	3.5	24
232	Generation of functional podocytes from human induced pluripotent stem cells. Stem Cell Research, 2016, 17, 130-139.	0.7	66
233	Diets for patients with chronic kidney disease, should we reconsider?. BMC Nephrology, 2016, 17, 80.	1.9	51
234	Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?. American Journal of Physiology - Renal Physiology, 2016, 310, F335-F341.	3.0	45

#	ARTICLE	IF	CITATIONS
235	Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3405-3412.	0.5	8
236	Recognition and management of acute kidney injury in the International Society of Nephrology Oby25 Global Snapshot: a multinational cross-sectional study. <i>Lancet, The</i> , 2016, 387, 2017-2025.	12.2	317
237	Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation. <i>Pharmacological Research</i> , 2016, 108, 16-22.	7.3	12
238	Progression, Remission and Regression of Chronic Renal Diseases. <i>Nephron</i> , 2016, 134, 20-24.	1.8	32
239	Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. <i>The Lancet Global Health</i> , 2016, 4, e307-e319.	6.0	385
240	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap. <i>Kidney International Reports</i> , 2016, 1, 327-339.	0.9	1
241	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 682-699.	3.0	177
242	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 700-704.	3.0	158
243	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	12.2	782
244	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	12.2	1,680
245	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	12.2	5,141
246	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	12.2	4,401
247	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	12.2	604
248	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	12.2	433
249	Early renin–angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 64-71.	4.6	60
250	Podocyte–actin dynamics in health and disease. <i>Nature Reviews Nephrology</i> , 2016, 12, 692-710.	9.7	161
251	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016, 68, 873-881.	2.0	28
252	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , 2016, 3, e361-e387.	4.5	469

#	ARTICLE	IF	CITATIONS
253	The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. <i>BMC Nephrology</i> , 2016, 17, 141.	1.9	48
254	Mesenchymal Stem Cells in Kidney Repair. <i>Methods in Molecular Biology</i> , 2016, 1416, 89-107.	1.4	44
255	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. <i>Nephron</i> , 2016, 132, 59-69.	1.8	37
256	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. <i>JAMA Pediatrics</i> , 2016, 170, 267.	6.4	505
257	Pharmacotherapy options for membranous nephropathy. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 185-196.	0.7	0
258	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 758-768.	1.9	29
259	Recent advances in immunosuppression and acquired immune tolerance in renal transplants. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F446-F453.	3.0	5
260	Prevention programs for chronic kidney disease in low-income countries. <i>Internal and Emergency Medicine</i> , 2016, 11, 385-389.	2.3	31
261	Acute kidney injury in low-income and middle-income countries: no longer a death sentence. <i>The Lancet Global Health</i> , 2016, 4, e216-e217.	6.0	22
262	Kidney disease in children: latest advances and remaining challenges. <i>Nature Reviews Nephrology</i> , 2016, 12, 182-191.	9.7	32
263	Mesenchymal stromal cells in renal transplantation: opportunities and challenges. <i>Nature Reviews Nephrology</i> , 2016, 12, 241-253.	9.7	134
264	Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1022-1030.e4.	4.8	48
265	Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 818-824.e6.	4.8	64
266	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. <i>Journal of Biological Chemistry</i> , 2016, 291, 8214-8230a.	3.5	12
267	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 785-794.	4.6	36
268	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. <i>Molecular Immunology</i> , 2016, 71, 131-142.	2.4	134
269	Novel Biomarkers for Renal Diseases? None for the Moment (but One). <i>SLAS Discovery</i> , 2016, 21, 655-670.	2.8	34
270	The Lancet Kidney Campaign: an opportunity for partnerships. <i>Lancet</i> , 2016, 387, 1038-1039.	12.2	2

#	ARTICLE	IF	CITATIONS
271	Italy, the Land of Holy Miracles” revisited. <i>Lancet, The</i> , 2016, 387, 11-12.	12.2	2
272	Liver transplantation for aHUS: still needed in the eculizumab era?. <i>Pediatric Nephrology</i> , 2016, 31, 759-768.	1.8	22
273	Functional Human Podocytes Generated in Organoids from Amniotic Fluid Stem Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1400-1411.	0.5	53
274	B7a1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 999-1005.	0.5	30
275	Association of <i>CFHR1</i> homozygous deletion with acute myelogenous leukemia in the European population. <i>Leukemia and Lymphoma</i> , 2016, 57, 1234-1237.	1.4	6
276	Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 699-705.	0.5	37
277	The Onset and Resolution of Renal Fibrosis. , 2016, , 351-366.		1
278	Sirtuin3 Dysfunction Is the Key Determinant of Skeletal Muscle Insulin Resistance by Angiotensin II. <i>PLoS ONE</i> , 2015, 10, e0127172.	2.4	16
279	Sirtuin 3 dependent mitochondrial dynamic improvements protect against acute kidney injury. <i>Journal of Clinical Investigation</i> , 2015, 125, 715-726.	6.7	349
280	Eliminating Treatable Deaths Due to Acute Kidney Injury in Resource-Poor Settings. <i>Seminars in Dialysis</i> , 2015, 28, 193-197.	1.4	19
281	A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study. <i>Nephron</i> , 2015, 130, 13-20.	1.8	9
282	Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. <i>American Journal of Kidney Diseases</i> , 2015, 66, 359-375.	2.0	137
283	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 743-800.	12.2	5,124
284	Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease. <i>Nephron</i> , 2015, 129, 52-61.	1.8	44
285	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1011-1019.	4.6	47
286	Direct Reprogramming of Human Bone Marrow Stromal Cells into Functional Renal Cells Using Cell-free Extracts. <i>Stem Cell Reports</i> , 2015, 4, 685-698.	4.8	27
287	Dual Renin-Angiotensin System Blockade for Nephroprotection: Still under Scrutiny. <i>Nephron</i> , 2015, 129, 39-41.	1.8	20
288	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. <i>Kidney International</i> , 2015, 87, 1061-1073.	5.6	352

#	ARTICLE	IF	CITATIONS
289	Spectrum of Steroid-Resistant and Congenital Nephrotic Syndrome in Children. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 592-600.	4.6	233
290	Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 706-712.	0.8	94
291	Low-Dose RATG with or without Basiliximab in Renal Transplantation: A Matched-Cohort Observational Study. <i>American Journal of Nephrology</i> , 2015, 41, 16-27.	3.2	4
292	Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 181-190.	11.0	121
293	Podocyte dysfunction in atypical haemolytic uraemic syndrome. <i>Nature Reviews Nephrology</i> , 2015, 11, 245-252.	9.7	49
294	Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury. <i>Scientific Reports</i> , 2015, 5, 8826.	3.5	92
295	Maintenance Dialysis throughout the World in Years 1990 and 2010. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2621-2633.	0.5	163
296	Acute Kidney Injury in Poor Countries Should No Longer Be a Death Sentence: The ISN "0 by 25" Project. <i>Annals of Nutrition and Metabolism</i> , 2015, 66, 42-44.	2.0	11
297	Nephroprotection by dual RAS blockade" a welcome back. <i>Nature Reviews Nephrology</i> , 2015, 11, 507-508.	9.7	4
298	Organoid Models and Applications in Biomedical Research. <i>Nephron</i> , 2015, 130, 191-199.	1.8	2,418
299	Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?. <i>European Journal of Heart Failure</i> , 2015, 17, 468-471.	7.6	19
300	International Society of Nephrology's Oby25 initiative for acute kidney injury (zero preventable deaths) Tj ETQq0 0 0 rgBT /Overlock 10 1	12.2	825
301	Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2545-2558.	0.5	297
302	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. <i>EBioMedicine</i> , 2015, 2, 456-466.	6.1	26
303	Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 79-85.	1.6	23
304	Rare diseases and effective treatments: are we delivering?. <i>Lancet, The</i> , 2015, 385, 750-752.	12.2	48
305	Nephrology research"the past, present and future. <i>Nature Reviews Nephrology</i> , 2015, 11, 677-687.	9.7	23
306	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. <i>American Journal of Kidney Diseases</i> , 2015, 66, 1067-1070.	2.0	25

#	ARTICLE	IF	CITATIONS
307	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2002-2012.	4.6	13
308	Acute kidney injury: more awareness needed, globally. <i>Lancet, The</i> , 2015, 386, 1425-1427.	12.2	20
309	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 884.	7.1	548
310	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€“2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	12.2	1,594
311	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	12.2	2,274
312	Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1568-1574.	4.6	33
313	Effective CKD Care in European Countries: Challenges and Opportunities for Health Policy. <i>American Journal of Kidney Diseases</i> , 2015, 65, 15-25.	2.0	72
314	Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?. <i>Nephron Clinical Practice</i> , 2015, 128, 261-269.	2.1	45
315	A Novel Atypical Hemolytic Uremic Syndromeâ€“Associated Hybrid CFHR1/CFH Gene Encoding a Fusion Protein That Antagonizes Factor Hâ€“Dependent Complement Regulation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 209-219.	0.5	89
316	Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1732-1746.	0.5	213
317	MicroRNAs in kidney physiology and disease. <i>Nature Reviews Nephrology</i> , 2015, 11, 23-33.	9.7	319
318	Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1205-1214.	0.5	52
319	Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. <i>Pediatric Nephrology</i> , 2015, 30, 167-172.	1.8	64
320	Sirtuin 3 in acute kidney injury. <i>Oncotarget</i> , 2015, 6, 16814-16815.	1.8	4
321	Need for chronic kidney disease prevention programs in disadvantaged populations. <i>Clinical Nephrology</i> , 2015, 83 (2015), 42-48.	0.8	7
322	Successes and Disappointments with Clinical Islet Transplantation. , 2015, , 1245-1274.		0
323	Current Status of Islet Transplantation. , 2014, , 583-598.		0
324	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv26-iv32.	0.8	12

#	ARTICLE	IF	CITATIONS
325	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 572-581.	3.2	34
326	ISNâ€™ACCTS: global initiatives to improve clinical research. <i>Nature Reviews Nephrology</i> , 2014, 10, 426-427.	9.7	3
327	Stamina therapies: Time to call a halt. <i>Nature</i> , 2014, 506, 434-434.	36.3	2
328	Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. <i>BMJ Open</i> , 2014, 4, e003536.	2.1	114
329	Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1786-1798.	0.5	53
330	An Unanticipated Role for Survivin in Organ Transplant Damage. <i>American Journal of Transplantation</i> , 2014, 14, 1046-1060.	5.0	9
331	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv15-iv25.	0.8	186
332	Renal Bioengineering with Scaffolds Generated from Rat and Pig Kidneys. <i>Nephron Experimental Nephrology</i> , 2014, 126, 113-118.	2.3	18
333	Mesenchymal stromal cells to promote kidney transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 47-53.	1.6	31
334	Cardiovascular risk assessment in low-resource settings. <i>Journal of Hypertension</i> , 2014, 32, 951-960.	0.5	73
335	Nephrology in developing countries: the ISN's story. <i>Lancet, The</i> , 2014, 383, 1271-1272.	12.2	18
336	Mortality landscape in the Global Burden of Diseases, Injuries and Risk Factors Study. <i>European Journal of Internal Medicine</i> , 2014, 25, 1-5.	2.3	23
337	Recellularization of Well-Preserved Acellular Kidney Scaffold Using Embryonic Stem Cells. <i>Tissue Engineering - Part A</i> , 2014, 20, 1486-1498.	3.3	171
338	Cardiovascular complications in atypical haemolytic uraemic syndrome. <i>Nature Reviews Nephrology</i> , 2014, 10, 174-180.	9.7	64
339	Î²-Arrestin-1 Drives Endothelin-1â€™Mediated Podocyte Activation and Sustains Renal Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 523-533.	0.5	64
340	Key fibrogenic mediators: old players. Reninâ€™angiotensin system. <i>Kidney International Supplements</i> , 2014, 4, 58-64.	13.5	80
341	The Nrf2 pathway in the progression of renal disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, i19-i24.	0.8	117
342	Kidney Transplantation From a Donor With Acute Kidney Injury: An Unexpected Outcome. <i>American Journal of Transplantation</i> , 2014, 14, 977-978.	5.0	1

#	ARTICLE	IF	CITATIONS
343	Nephrons are generated via a series of committed progenitors. <i>Nature Reviews Nephrology</i> , 2014, 10, 491-491.	9.7	0
344	The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1083-1093.	0.5	229
345	Management of chronic kidney disease and its risk factors in eastern Nepal. <i>The Lancet Global Health</i> , 2014, 2, e506-e507.	6.0	15
346	High serum cholesterol: a missed risk factor for chronic kidney disease mortality. <i>Lancet Diabetes and Endocrinology,the</i> , 2014, 2, 613-614.	11.0	3
347	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 1005-1070.	12.2	801
348	Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 850-863.	0.5	206
349	Dreaming of normoglycaemia with fewer diet restrictions. <i>Lancet Diabetes and Endocrinology,the</i> , 2014, 2, 350-351.	11.0	1
350	Chronic kidney disease in sub-Saharan Africa: a public health priority. <i>The Lancet Global Health</i> , 2014, 2, e124-e125.	6.0	8
351	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. <i>Kidney International</i> , 2014, 86, 246-250.	5.6	84
352	Rare inherited kidney diseases: challenges, opportunities, and perspectives. <i>Lancet, The</i> , 2014, 383, 1844-1859.	12.2	200
353	CD133+ renal stem cells always co-express CD24 in adult human kidney tissue. <i>Stem Cell Research</i> , 2014, 12, 828-829.	0.7	41
354	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , 2014, 124, 1715-1726.	1.4	298
355	International Society of Nephrology's Perspective on the Emergence of Chronic Kidney Diseases of Unknown/Undetermined Etiology. <i>MEDICC Review</i> , 2014, 16, 75.	0.6	8
356	The Glomerulus: Mechanisms and Patterns of Injury†. , 2014, , .		2
357	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013, 37, 212-222.	3.2	83
358	Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis. <i>American Journal of Kidney Diseases</i> , 2013, 62, 984-992.	2.0	34
359	Monogenic diseases that can be cured by liver transplantation. <i>Journal of Hepatology</i> , 2013, 59, 595-612.	4.0	119
360	Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. <i>Age</i> , 2013, 35, 993-1005.	3.0	40

#	ARTICLE	IF	CITATIONS
361	Advances in the Pathology of Glomerular Diseases. Contributions To Nephrology, 2013, 181, 12-21.	0.0	11
362	Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Translational Research, 2013, 161, 73-84.	5.2	107
363	Angiotensin II Contributes to Diabetic Renal Dysfunction in Rodents and Humans via Notch1/Snail Pathway. American Journal of Pathology, 2013, 183, 119-130.	4.2	39
364	Overview of Complement Activation and Regulation. Seminars in Nephrology, 2013, 33, 479-492.	1.6	648
365	Self-Specific Memory Regulatory T Cells Protect Embryos at Implantation in Mice. Journal of Immunology, 2013, 191, 2273-2281.	0.8	99
366	Idiopathic membranous nephropathy: back to the future?. Lancet, The, 2013, 381, 706-708.	12.2	8
367	Acute renal failure: an unacceptable death sentence globally. Lancet, The, 2013, 382, 2041-2042.	12.2	46
368	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transplant International, 2013, 26, 867-878.	1.8	151
369	Role of Proteinuria in the Progression of Renal Disease. , 2013, , 2961-2983.		1
370	Transfer of Growth Factor Receptor mRNA Via Exosomes Unravels the Regenerative Effect of Mesenchymal Stem Cells. Stem Cells and Development, 2013, 22, 772-780.	2.2	305
371	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet, The, 2013, 382, 1485-1495.	12.2	222
372	Nature and Mediators of Parietal Epithelial Cell Activation in Glomerulonephritides of Human and Rat. American Journal of Pathology, 2013, 183, 1769-1778.	4.2	61
373	Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial) Tj ETQq1 1 0.784314 rgBT / Diseases, 2013, 61, 238-246.	2.0	21
374	Recent Progress in the Pathophysiology and Treatment of FSGS Recurrence. American Journal of Transplantation, 2013, 13, 266-274.	5.0	98
375	Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. British Journal of Clinical Pharmacology, 2013, 76, 516-523.	2.7	147
376	Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nature Reviews Nephrology, 2013, 9, 137-146.	9.7	174
377	The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney International, 2013, 84, 164-173.	5.6	136
378	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2013, 1, 19-27.	11.0	37

#	ARTICLE	IF	CITATIONS
379	Kidney failure: aims for the next 10 years and barriers to success. <i>Lancet, The</i> , 2013, 382, 353-362.	12.2	50
380	Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies. <i>Stem Cell Reviews and Reports</i> , 2013, 9, 65-79.	6.2	125
381	Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations. <i>American Journal of Transplantation</i> , 2013, 13, 2201-2206.	5.0	52
382	Meta-analyses can misdirect decisions on treatment. <i>Nature Reviews Nephrology</i> , 2013, 9, 311-312.	9.7	4
383	Renal progenitors in non-diabetic and diabetic nephropathies. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 13-20.	7.2	63
384	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2013, 369, 2492-2503.	30.7	871
385	Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. <i>Kidney International</i> , 2013, 84, 1237-1245.	5.6	70
386	Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 475-486.	0.5	313
387	ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy. <i>Diabetes</i> , 2013, 62, 3599-3609.	0.9	25
388	Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 704-712.	2.1	59
389	Mesenchymal stromal cells to promote solid organ transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 51-58.	1.6	70
390	Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, F808-F819.	3.0	90
391	In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development. <i>Journal of Immunology</i> , 2013, 191, 2818-2828.	0.8	77
392	Mapping KT interventions to barriers and facilitators. , 2013, , 137-149.		12
393	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2841-2850.	0.8	21
394	Dual RAS blockade controversy resolved. <i>Nature Reviews Nephrology</i> , 2013, 9, 640-640.	9.7	3
395	Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome. <i>New England Journal of Medicine</i> , 2013, 368, 2169-2181.	30.7	1,307
396	A Novel Strategy to Enhance Mesenchymal Stem Cell Migration Capacity and Promote Tissue Repair in an Injury Specific Fashion. <i>Cell Transplantation</i> , 2013, 22, 423-436.	2.6	109

#	ARTICLE	IF	CITATIONS
397	Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting. Transplantation, 2013, 96, 234-238.	1.1	73
398	Prednisolone plus chlorambucil preserved renal function in membranous nephropathy. Annals of Internal Medicine, 2013, 158, JC9.	9.7	0
399	Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor. PLoS ONE, 2013, 8, e70775.	2.4	77
400	Successes and Disappointments with Clinical Islet Transplantation. , 2013, , 1-27.		0
401	Prevalence of Hypertension and Diabetes and Coexistence of Chronic Kidney Disease and Cardiovascular Risk in the Population of the Republic of Moldova. International Journal of Hypertension, 2012, 2012, 1-8.	1.4	11
402	Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney International, 2012, 81, 903-918.	5.6	36
403	Eculizumab in a Patient with Dense-Deposit Disease. New England Journal of Medicine, 2012, 366, 1161-1163.	30.7	141
404	Proteinuria should be used as a surrogate in CKD. Nature Reviews Nephrology, 2012, 8, 301-306.	9.7	126
405	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. BMJ Open, 2012, 2, e001357.	2.1	32
406	In Vivo Maturation of Functional Renal Organoids Formed from Embryonic Cell Suspensions. Journal of the American Society of Nephrology: JASN, 2012, 23, 1857-1868.	0.5	160
407	Human Amniotic Fluid Stem Cell Preconditioning Improves Their Regenerative Potential. Stem Cells and Development, 2012, 21, 1911-1923.	2.2	112
408	Non-muscle myosins and the podocyte. CKJ: Clinical Kidney Journal, 2012, 5, 94-101.	3.0	16
409	Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice. Journal of Immunology, 2012, 189, 3661-3668.	0.8	35
410	Dealing with Renin-Angiotensin Inhibitors, Don't Mind Serum Creatinine. American Journal of Nephrology, 2012, 36, 427-429.	3.2	12
411	The ERA-EDTA Working Group on inherited kidney disorders. Nephrology Dialysis Transplantation, 2012, 27, 67-69.	0.8	12
412	Chronic kidney disease: a research and public health priority. Nephrology Dialysis Transplantation, 2012, 27, iii19-iii26.	0.8	71
413	Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. CardioRenal Medicine, 2012, 2, 1-10.	1.9	105
414	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood, 2012, 120, 440-448.	1.4	109

#	ARTICLE	IF	CITATIONS
415	Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. <i>Blood</i> , 2012, 119, 3269-3275.	1.4	107
416	Ethical disputes still beset Italian medicine 150 years after Count Cavour's death. <i>Lancet, The</i> , 2012, 379, 1068-1073.	12.2	5
417	Cavour's death and the political difficulties of Italian medicine – Author's reply. <i>Lancet, The</i> , 2012, 380, 108-109.	12.2	0
418	STEC-HUS, atypical HUS and TTP are all diseases of complement activation. <i>Nature Reviews Nephrology</i> , 2012, 8, 622-633.	9.7	339
419	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2129-2143.	12.2	1,045
420	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2197-2223.	12.2	7,201
421	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2095-2128.	12.2	11,297
422	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2163-2196.	12.2	6,546
423	Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. <i>Pediatric Nephrology</i> , 2012, 27, 1989-1993.	1.8	19
424	Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1717-1724.	0.5	83
425	MicroRNA-324-3p Promotes Renal Fibrosis and Is a Target of ACE Inhibition. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1496-1505.	0.5	86
426	Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, F1370-F1381.	3.0	90
427	Mechanisms and Treatment of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1917-1928.	0.5	231
428	Rituximab in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1416-1425.	0.5	263
429	E. coli O104:H4 German outbreak: a missed opportunity. <i>Nature Reviews Nephrology</i> , 2012, 8, 558-560.	9.7	9
430	Time-Domain and Spectral-Domain Optical Coherence Tomography of Retinal Nerve Fiber Layer in MS Patients and Healthy Controls. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-7.	1.4	20
431	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. <i>Journal of Transplantation</i> , 2012, 2012, 1-7.	0.5	9
432	Spatial Correlation and Ergodic Capacity of MIMO Channel in Reverberation Chamber. <i>International Journal of Antennas and Propagation</i> , 2012, 2012, 1-7.	1.3	15

#	ARTICLE	IF	CITATIONS
433	Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2061-2068.	9.3	266
434	Sodium Intake, ACE Inhibition, and Progression to ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 165-173.	0.5	281
435	Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 2373-2383.	5.0	155
436	Mechanisms and Consequences of Proteinuria. , 2012, , 1972-1999.		0
437	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 412-422.	4.6	274
438	Bone Marrow Mesenchymal Stem Cells in Organ Repair and Strategies to Optimize their Efficacy. , 2011, , 299-312.		1
439	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011, 79, 1331-1340.	5.6	630
440	Inhibiting Angiotensin-Converting Enzyme Promotes Renal Repair by Limiting Progenitor Cell Proliferation and Restoring the Glomerular Architecture. <i>American Journal of Pathology</i> , 2011, 179, 628-638.	4.2	101
441	Intermediate Volume on Computed Tomography Imaging Defines a Fibrotic Compartment that Predicts Glomerular Filtration Rate Decline in Autosomal Dominant Polycystic Kidney Disease Patients. <i>American Journal of Pathology</i> , 2011, 179, 619-627.	4.2	19
442	Initial combination therapy for treatment of hypertension. <i>Lancet, The</i> , 2011, 377, 1491.	12.2	1
443	A German outbreak of haemolytic uraemic syndrome. <i>Lancet, The</i> , 2011, 378, 1057-1058.	12.2	31
444	Aging and the kidney. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 312-317.	2.1	42
445	Both Darbepoetin Alfa and Carbamylated Erythropoietin Prevent Kidney Graft Dysfunction Due to Ischemia/Reperfusion in Rats. <i>Transplantation</i> , 2011, 92, 271-279.	1.1	25
446	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. <i>Journal of Hypertension</i> , 2011, 29, 207-216.	0.5	62
447	Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. <i>Journal of Hypertension</i> , 2011, 29, 2031-2037.	0.5	3
448	Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. <i>Transplant International</i> , 2011, 24, 829-838.	1.8	22
449	Erythropoietin enhances immunostimulatory properties of immature dendritic cells. <i>Clinical and Experimental Immunology</i> , 2011, 165, 202-210.	2.7	25
450	Optimizing Allocation of Kidneys from Older Donors. <i>American Journal of Transplantation</i> , 2011, 11, 182-182.	5.0	3

#	ARTICLE	IF	CITATIONS
451	Membranous Nephropathy Associated With IgG4-Related Disease. American Journal of Kidney Diseases, 2011, 58, 272-275.	2.0	65
452	PPAR α P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrology Dialysis Transplantation, 2011, 26, 4011-4016.	0.8	28
453	Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. American Journal of Physiology - Renal Physiology, 2011, 300, F1291-F1300.	3.0	14
454	Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney. European Heart Journal, 2011, 32, 2476-2478.	2.4	57
455	Thrombotic Microangiopathies: From Animal Models to Human Disease and Cure. Contributions To Nephrology, 2011, 169, 337-350.	0.0	13
456	<i>MYO1E</i> Mutations and Childhood Familial Focal Segmental Glomerulosclerosis. New England Journal of Medicine, 2011, 365, 295-306.	30.7	228
457	Staging CKD: can we rely on estimated GFRs?. Nature Reviews Nephrology, 2011, 7, 307-308.	9.7	0
458	Early-Childhood Membranous Nephropathy Due to Cationic Bovine Serum Albumin. New England Journal of Medicine, 2011, 364, 2101-2110.	30.7	198
459	Cells for Treating Organ Damage: How Long Will We Need Them?. Journal of the American Society of Nephrology: JASN, 2011, 22, 590-592.	0.5	0
460	Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. Journal of the American Society of Nephrology: JASN, 2011, 22, 1923-1930.	0.5	190
461	Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1400-1402.	0.5	23
462	Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study. American Journal of Nephrology, 2011, 33, 461-468.	3.2	70
463	Old Donors for Kidney Transplantation: How Old?. Gerontology, 2011, 57, 513-520.	2.8	21
464	Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. Hypertension, 2011, 58, 776-783.	5.0	89
465	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. European Heart Journal, 2011, 32, 1493-1499.	2.4	115
466	Hypertension after kidney transplantation. Journal of Hypertension, 2011, 29, 2310-2311.	0.5	7
467	Embryonic Stem Cells, Derived Either after In Vitro Fertilization or Nuclear Transfer, Prolong Survival of Semiallogeneic Heart Transplants. Journal of Immunology, 2011, 186, 4164-4174.	0.8	9
468	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. Journal of Immunology, 2011, 187, 172-180.	0.8	223

#	ARTICLE	IF	CITATIONS
469	ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1122-1128.	0.5	123
470	A phase 1, single-dose study of fresolimumab, an anti-TGF- β 2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis. <i>Kidney International</i> , 2011, 79, 1236-1243.	5.6	230
471	The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. <i>Kidney International</i> , 2011, 80, 1258-1270.	5.6	1,154
472	Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis. <i>American Journal of Nephrology</i> , 2011, 34, 367-372.	3.2	47
473	Distinct cardiac and renal effects of ET _A receptor antagonist and ACE inhibitor in experimental type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, F1114-F1123.	3.0	56
474	Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives. <i>Current Diabetes Reviews</i> , 2011, 7, 190-200.	1.4	37
475	Microvascular and Macrovascular Diseases of the Kidney. , 2011, , 1297-1331.		2
476	Life-Sparing Effect of Human Cord Blood-Mesenchymal Stem Cells in Experimental Acute Kidney Injury. <i>Stem Cells</i> , 2010, 28, 513-522.	3.6	161
477	Systems biology to battle vascular disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1019-1022.	0.8	22
478	Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 731-737.	1.6	23
479	Omega-3 Polyunsaturated Fatty Acids Affect Sirolimus Exposure in Kidney Transplant Recipients on Calcineurin Inhibitor-Free Regimen. <i>Transplantation</i> , 2010, 89, 126-127.	1.1	3
480	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial. <i>Diabetes Care</i> , 2010, 33, e133-e133.	9.3	0
481	Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. <i>Journal of Hypertension</i> , 2010, 28, 186-193.	0.5	18
482	Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). <i>Transplantation</i> , 2010, 90, 124-126.	1.1	67
483	Successes and Disappointments with Clinical Islet Transplantation. <i>Advances in Experimental Medicine and Biology</i> , 2010, 654, 749-769.	9.0	16
484	Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1844-1859.	4.6	851
485	Angiotensin receptors as determinants of life span. <i>Pflugers Archiv European Journal of Physiology</i> , 2010, 459, 325-332.	2.8	60
486	Burden of CKD, Proteinuria, and Cardiovascular Risk Among Chinese, Mongolian, and Nepalese Participants in the International Society of Nephrology Screening Programs. <i>American Journal of Kidney Diseases</i> , 2010, 56, 915-927.	2.0	58

#	ARTICLE	IF	CITATIONS
487	Low-Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy. American Journal of Transplantation, 2010, 10, 1336.	5.0	8
488	Thrombotic Microangiopathy After Kidney Transplantation. American Journal of Transplantation, 2010, 10, 1517-1523.	5.0	193
489	Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Molecular Medicine, 2010, 2, 247-257.	6.9	612
490	The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis and Tissue Repair, 2010, 3, 7.	3.3	37
491	Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?. Pharmaceuticals, 2010, 3, 1-9.	3.9	15
492	Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial. Journal of Ophthalmology, 2010, 2010, 1-9.	1.4	16
493	Introduction to Focus on Fabry Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 359.	4.6	2
494	Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens. Hypertension, 2010, 56, 533-539.	5.0	25
495	Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1928-1938.	4.6	37
496	Oral Acetyl- <sc>L</sc>-Carnitine Therapy and Insulin Resistance. Hypertension, 2010, 55, e26.	5.0	7
497	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 1146-1155.	30.7	440
498	Enzyme Replacement Therapy and Fabry Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 371-378.	4.6	21
499	Prevention and Transplantation in Chronic Kidney Disease: What Is Achievable in Emerging Countries?. Nephron Clinical Practice, 2010, 115, c122-c132.	2.1	11
500	Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study. Nephron Clinical Practice, 2010, 115, c154-c160.	2.1	81
501	Reducing Polycystic Liver Volume in ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 783-789.	4.6	128
502	Thrombotic Microangiopathies, Including Hemolytic Uremic Syndrome. , 2010, , 344-355.		7
503	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, 1954-1956.	9.3	29
504	Do mTOR inhibitors still have a future in ADPKD?. Nature Reviews Nephrology, 2010, 6, 696-698.	9.7	13

#	ARTICLE	IF	CITATIONS
505	Sirolimus Therapy to Halt the Progression of ADPKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1031-1040.	0.5	158
506	Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy. Hypertension, 2010, 55, 1206-1209.	5.0	40
507	Imaging of the Porous Ultrastructure of the Glomerular Epithelial Filtration Slit. Journal of the American Society of Nephrology: JASN, 2010, 21, 2081-2089.	0.5	91
508	Comment on: Robertson (2010) Islet Transplantation a Decade Later and Strategies for Filling a Half-Full Glass. Diabetes;59:1285-1291. Diabetes, 2010, 59, e13-e13.	0.9	3
509	Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. American Journal of Physiology - Renal Physiology, 2010, 299, F1203-F1211.	3.0	49
510	ERA-EDTA Immunonephrology working group. Nephrology Dialysis Transplantation, 2010, 25, 1706-1707.	0.8	1
511	The Glomerulus: Mechanisms of Injury*. , 2010, , 245-261.		0
512	Non-immune interventions to protect kidney allografts in the long term. Kidney International, 2010, 78, S71-S75.	5.6	17
513	Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney International, 2010, 78, 1068-1074.	5.6	47
514	The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nature Reviews Nephrology, 2010, 6, 319-330.	9.7	259
515	Which antihypertensive drugs are the most nephroprotective and why?. Expert Opinion on Pharmacotherapy, 2010, 11, 2651-2663.	1.9	20
516	THE DIABETIC CKD PATIENTâ€™A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care, 2010, 36, 34-46.	1.1	15
517	Kidney regeneration. Lancet, The, 2010, 375, 1310-1317.	12.2	128
518	Exciting times for renal medicine. Lancet, The, 2010, 375, 1227-1228.	12.2	1
519	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet, The, 2010, 376, 1543-1551.	12.2	620
520	Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology, 2010, 30, 395-408.	1.6	32
521	Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 2010, , 349-364.		0
522	Nondiabetic Kidney Disease. , 2010, , 341-356.		0

#	ARTICLE	IF	CITATIONS
523	Pathophysiology of Chronic Kidney Disease. , 2009, , 422-435.		1
524	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 2009, 101, 233-238.	3.5	85
525	Low Mortality and Key Aspects of Delivery of Care for End-Stage Renal Disease in Italy. Scientific World Journal, The, 2009, 9, 349-359.	2.3	4
526	Thrice-Weekly In-Center Nocturnal Hemodialysis: An Effective Strategy to Optimize Chronic Dialysis Therapy. International Journal of Artificial Organs, 2009, 32, 12-19.	1.5	17
527	The role of chemokines in progressive renal disease. Frontiers in Bioscience - Landmark, 2009, Volume, 1815.	3.1	43
528	Limited Sampling Strategies for the Estimation of Sirolimus Daily Exposure in Kidney Transplant Recipients on a Calcineurin Inhibitor-Free Regimen. Journal of Clinical Pharmacology, 2009, 49, 773-781.	2.1	7
529	Aldosterone and progression of kidney disease. Therapeutic Advances in Cardiovascular Disease, 2009, 3, 133-143.	2.2	18
530	Renal Progenitor Cells Contribute to Hyperplastic Lesions of Podocytopathies and Crescentic Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 2593-2603.	0.5	176
531	The Toll-IL-1R Member Tir8/SIGIRR Negatively Regulates Adaptive Immunity against Kidney Grafts. Journal of Immunology, 2009, 183, 4249-4260.	0.8	46
532	Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenetics and Genomics, 2009, 19, 695-703.	1.5	21
533	Successful Split Liver-Kidney Transplant for Factor H Associated Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 201-206.	4.6	61
534	Treatment of Chronic Proteinuric Kidney Disease. Hypertension, 2009, 54, 29-31.	5.0	3
535	Rare but Relevant Kidney Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1701-1704.	4.6	0
536	Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrology Dialysis Transplantation, 2009, 24, 1355-1358.	0.8	37
537	Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. Kidney International, 2009, 75, 1050-1059.	5.6	29
538	Increased angiotensin-receptor blocking is not the first option. Nature Reviews Nephrology, 2009, 5, 367-368.	9.7	12
539	Is the ONTARGET renal substudy actually off target?. Nature Reviews Nephrology, 2009, 5, 436-437.	9.7	44
540	Outcome of Renal Transplantation from Very Old Donors. New England Journal of Medicine, 2009, 360, 1464-1465.	30.7	29

#	ARTICLE	IF	CITATIONS
541	Thrombomodulin Mutations in Atypical Hemolytic-Uremic Syndrome. <i>New England Journal of Medicine</i> , 2009, 361, 345-357.	30.7	502
542	Rituximab for membranous nephropathy and immune disease: less might be enough. <i>Nature Clinical Practice Nephrology</i> , 2009, 5, 76-77.	1.0	18
543	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. <i>Kidney International</i> , 2009, 76, 960-967.	5.6	58
544	Medicine and art: one culture?. <i>Kidney International</i> , 2009, 75, 347-348.	5.6	1
545	Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F1448-F1456.	3.0	115
546	The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2009, 30, 280-286.	3.2	35
547	What not to learn from a meta-analysis. <i>Nature Reviews Nephrology</i> , 2009, 5, 186-188.	9.7	15
548	Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk. <i>Hypertension</i> , 2009, 54, 567-574.	5.0	104
549	Impact of the PPAR- γ 2 Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT. <i>Diabetes</i> , 2009, 58, 2920-2929.	0.9	29
550	Mycophenolate Mofetil Versus Azathioprine in Organ Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 2856-2857.	5.0	14
551	Kidney Injury Molecule 1: In Search of Biomarkers of Chronic Tubulointerstitial Damage and Disease Progression. <i>American Journal of Kidney Diseases</i> , 2009, 53, 1-4.	2.0	123
552	Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2009, 54, 59-69.	2.0	61
553	Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. <i>Current Hypertension Reports</i> , 2009, 11, 118-124.	3.4	7
554	Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. <i>Gene Therapy</i> , 2009, 16, 1373-1379.	4.8	14
555	Treatment of Bleeding in Dialysis Patients. <i>Seminars in Dialysis</i> , 2009, 22, 279-286.	1.4	131
556	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2009, 361, 2019-2032.	30.7	2,136
557	Bone Marrow-Derived Mesenchymal Stem Cells Improve Islet Graft Function in Diabetic Rats. <i>Transplantation Proceedings</i> , 2009, 41, 1797-1800.	0.6	128
558	Atypical Hemolytic-Uremic Syndrome. <i>New England Journal of Medicine</i> , 2009, 361, 1676-1687.	30.7	1,168

#	ARTICLE	IF	CITATIONS
559	Time to rethink immunosuppression by mTOR inhibitors?. Nature Reviews Nephrology, 2009, 5, 611-612.	9.7	10
560	Developing Regulatory-compliant Electronic Case Report Forms for Clinical Trials: Experience with The Demand Trial. Journal of the American Medical Informatics Association: JAMIA, 2009, 16, 404-408.	4.6	38
561	Podocyte Repopulation Contributes to Regression of Glomerular Injury Induced by Ace Inhibition. American Journal of Pathology, 2009, 174, 797-807.	4.2	93
562	Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet, The, 2009, 373, 1235-1236.	12.2	22
563	Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine, 2009, 360, 1395-1407.	30.7	1,806
564	Inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 166-170.	3.5	29
565	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. Transplantation, 2009, 88, 614-619.	1.1	64
566	Disruption of the Ang II type 1 receptor promotes longevity in mice. Journal of Clinical Investigation, 2009, 119, 524-530.	6.7	441
567	Mesenchymal Stem Cells and Their Use in Acute Renal Injury. , 2009, , 216-220.		0
568	Bleeding and Hemostasis in Acute Renal Failure. , 2009, , 385-390.		0
569	Acute Renal Failure in Kidney Transplant Recipients. , 2009, , 1660-1665.		0
570	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. Stem Cells, 2008, 26, 2075-2082.	3.6	353
571	Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nature Reviews Drug Discovery, 2008, 7, 936-953.	56.6	79
572	Translational Mini-Review Series on Complement Factor H: Therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clinical and Experimental Immunology, 2008, 151, 199-209.	2.7	31
573	Candesartan and renal protection: more than blocking angiotensin type 1 receptor?. Kidney International, 2008, 74, 1112-1114.	5.6	5
574	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2008, , 445-456.		0
575	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Molecular Immunology, 2008, 45, 95-105.	2.4	138
576	Decision time for pancreatic islet-cell transplantation. Lancet, The, 2008, 371, 883-884.	12.2	24

#	ARTICLE	IF	CITATIONS
577	Rare diseases: what's next?. Lancet, The, 2008, 371, 1978-1979.	12.2	32
578	Î²-cell transplantation for diabetes therapy – Authors' reply. Lancet, The, 2008, 372, 29-30.	12.2	6
579	Polymorphisms of <i>EDNRB</i> , <i>ATG</i> , and <i>ACE</i> genes in salt-sensitive hypertension This article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.. Canadian Journal of Physiology and Pharmacology, 2008, 86, 505-510.	1.6	42
580	Primer: strategies for identifying genes involved in renal disease. Nature Clinical Practice Nephrology, 2008, 4, 265-276.	1.0	18
581	Investigational drugs for diabetic nephropathy. Expert Opinion on Investigational Drugs, 2008, 17, 1487-1500.	4.2	11
582	Role of Proteinuria in Progression. , 2008, , 2563-2576.		1
583	Allograft Rejection: Acute and Chronic Studies. , 2008, 159, 122-134.		7
584	Lymphocyte depletion for kidney transplantation: back to the past?. Nature Clinical Practice Nephrology, 2008, 4, 534-535.	1.0	4
585	Islet transplantation: need for a time-out?. Nature Clinical Practice Nephrology, 2008, 4, 660-661.	1.0	5
586	Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells. Journal of Immunology, 2008, 181, 3933-3946.	0.8	407
587	Fractalkine and CX3CR1 Mediate Leukocyte Capture by Endothelium in Response to Shiga Toxin. Journal of Immunology, 2008, 181, 1460-1469.	0.8	39
588	Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes. Diabetes Care, 2008, 31, 1629-1634.	9.3	34
589	Treating the kidney to cure the heart. Kidney International, 2008, 74, S2-S3.	5.6	9
590	New strategies to prevent cardiovascular risk in chronic kidney disease. Kidney International, 2008, 74, S1.	5.6	1
591	Mutations in <i>FN1</i> cause glomerulopathy with fibronectin deposits. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2538-2543.	7.6	126
592	Effects of Rituximab on Morphofunctional Abnormalities of Membranous Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1652-1659.	4.6	53
593	Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation. Kidney International, 2008, 74, 1420-1428.	5.6	7
594	Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. The Cochrane Library, 2008, , CD003233.	2.9	39

#	ARTICLE	IF	CITATIONS
595	Novel therapies of lupus nephritis. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 156-161.	2.1	6
596	Effect of Seliciclib (CYC202, R-Roscovitin) on Lymphocyte Alloreactivity and Acute Kidney Allograft Rejection in Rat. <i>Transplantation</i> , 2008, 85, 1476-1482.	1.1	5
597	Pharmacokinetic/Pharmacodynamic Drug Interaction Between Rosiglitazone and Mycophenolate Mofetil in Kidney Transplantation: A Case Report. <i>Transplantation</i> , 2008, 85, 921-922.	1.1	10
598	Prevention of Chronic Renal Diseases in the Elderly. , 2008, , 231-255.		1
599	Treatment of Anemia and Bleeding in Chronic Kidney Disease. , 2008, , 756-764.		1
600	Kidney Failure Stabilizes after a Two-Decade Increase: Impact on Global (Renal and Cardiovascular) Health. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 146-150.	4.6	20
601	Complement hyperactivation may cause atypical haemolytic uraemic syndrome gain-of-function mutations in factor B. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2452-2454.	0.8	5
602	A mouse model of non-Shiga toxin-associated haemolytic uraemic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 462-465.	0.8	0
603	Inhibition of TGF- β 2 expression: A novel role for thiazolidinediones to implement renoprotection in diabetes. <i>Kidney International</i> , 2007, 72, 1419-1421.	5.6	10
604	Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation. <i>American Journal of Nephrology</i> , 2007, 27, 630-638.	3.2	12
605	How should patients with, or at risk of, cardiovascular disease be screened for chronic kidney disease?. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 126-127.	1.0	1
606	Albumin concentration in the Bowman's capsule: Multiphoton microscopy vs micropuncture technique. <i>Kidney International</i> , 2007, 72, 1410-1411.	5.6	23
607	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. <i>Kidney International</i> , 2007, 71, 1132-1141.	5.6	4
608	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. <i>Pharmacogenomics</i> , 2007, 8, 1127-1141.	1.4	89
609	Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 932-937.	4.6	156
610	More on Renal Disease Progression: Is Interstitial Inflammation Truly Protective?. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1630-1632.	0.5	1
611	Pharmacokinetics of Mycophenolate Sodium and Comparison with the Mofetil Formulation in Stable Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 1147-1155.	4.6	53
612	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. <i>Journal of Hypertension</i> , 2007, 25, 871-876.	0.5	23

#	ARTICLE	IF	CITATIONS
613	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. <i>Transplantation</i> , 2007, 84, 956-964.	1.1	95
614	Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. <i>Journal of Hypertension</i> , 2007, 25, 1921-1926.	0.5	132
615	Treatment With Pegylated Interferon and Ribavirin for Hepatitis C Virus-associated Severe Cryoglobulinemia in a Liver/Kidney Transplant Recipient. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 216-220.	2.4	36
616	DnIKK2-Transfected Dendritic Cells Induce a Novel Population of Inducible Nitric Oxide Synthase-Expressing CD4+CD25+ Cells with Tolerogenic Properties. <i>Transplantation</i> , 2007, 83, 474-484.	1.1	22
617	Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007, , 257-282.	0.1	0
618	Clinical perspectives in the prevention and treatment of chronic nephropathy, including an overview of the DEMAND Study. <i>Clinical Therapeutics</i> , 2007, 29, S64-S72.	2.3	1
619	Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2007, 44, 111-122.	2.4	116
620	Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. <i>Molecular Immunology</i> , 2007, 44, 1704-1708.	2.4	41
621	Target haemoglobin concentrations in chronic kidney disease. <i>Lancet, The</i> , 2007, 369, 1515.	12.2	0
622	Clinical update: immunosuppression minimisation. <i>Lancet, The</i> , 2007, 369, 1676-1678.	12.2	31
623	Minimisation of immunosuppression in transplantation – Authors' reply. <i>Lancet, The</i> , 2007, 370, 654.	12.2	0
624	Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats. <i>American Journal of Pathology</i> , 2007, 170, 1165-1177.	4.2	70
625	Latest treatment strategies for membranous nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3159-3171.	1.9	18
626	KIDNEY FAILURE STABILIZES AFTER AN INCREASE OVER 2 DECADES. <i>Journal of Renal Care</i> , 2007, 33, 100-104.	1.1	4
627	Involvement of renal tubular toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1569-1578.	7.0	62
628	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1629-1637.	7.0	48
629	The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. <i>Human Mutation</i> , 2007, 28, 222-234.	2.8	160
630	Misleading meta-analysis: a need to look beyond the headlines. <i>Diabetic Medicine</i> , 2007, 24, 587-591.	2.5	7

#	ARTICLE	IF	CITATIONS
631	Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. <i>British Journal of Dermatology</i> , 2007, 157, 49-57.	1.7	36
632	Successful Liver-Kidney Transplantation in Two Children With aHUS Caused by a Mutation in Complement Factor H. <i>American Journal of Transplantation</i> , 2007, 8, 071105081616017-???	5.0	86
633	Does remission of renal disease associated with antihypertensive treatment exist?. <i>Current Hypertension Reports</i> , 2007, 9, 160-165.	3.4	6
634	Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. <i>Current Hypertension Reports</i> , 2007, 9, 430-436.	3.4	21
635	What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 250-251.	1.0	2
636	Modeling of a parallel hybrid power audio amplifier. <i>Industrial Electronics Society (IECON), Annual Conference of IEEE</i> , 2006, , .	0.0	9
637	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , 2006, 96, 454-464.	3.5	73
638	Pathophysiologic Implications of Reduced Podocyte Number in a Rat Model of Progressive Glomerular Injury. <i>American Journal of Pathology</i> , 2006, 168, 42-54.	4.2	137
639	Permselective Dysfunction of Podocyte-Podocyte Contact upon Angiotensin II Unravels the Molecular Target for Renoprotective Intervention. <i>American Journal of Pathology</i> , 2006, 168, 1073-1085.	4.2	82
640	Shigatoxin-Induced Endothelin-1 Expression in Cultured Podocytes Autocrinally Mediates Actin Remodeling. <i>American Journal of Pathology</i> , 2006, 169, 1965-1975.	4.2	94
641	Renoprotective effects of renin-angiotensin-system inhibitors. <i>Lancet, The</i> , 2006, 367, 899-900.	12.2	36
642	Overview of randomised trials of ACE inhibitors. <i>Lancet, The</i> , 2006, 368, 555-556.	12.2	36
643	Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?. <i>Journal of Hepatology</i> , 2006, 44, 837-838.	4.0	5
644	Corrigendum to "Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?" [Hepatology 44 (2006) 837-838]. <i>Journal of Hepatology</i> , 2006, 45, 339.	4.0	0
645	Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). <i>Thrombosis and Haemostasis</i> , 2006, 95, 212-220.	3.5	87
646	Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. <i>Blood</i> , 2006, 107, 1943-1950.	1.4	63
647	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. <i>Blood</i> , 2006, 108, 1267-1279.	1.4	664
648	Angiotensin-receptor blockers for renal protection in Type 2 diabetes. <i>Aging Health</i> , 2006, 2, 295-301.	0.4	0

#	ARTICLE	IF	CITATIONS
649	The Regenerative Potential of Stem Cells in Acute Renal Failure. <i>Cell Transplantation</i> , 2006, 15, 111-117.	2.6	58
650	Mycophenolic Acid Formulation Affects Cyclosporine Pharmacokinetics in Stable Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 643-649.	2.2	3
651	Is Mycophenolate Mofetil Better Than Azathioprine in Organ Transplantation?. <i>Transplantation</i> , 2006, 82, 1242-1243.	1.1	0
652	Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. <i>Journal of Hypertension</i> , 2006, 24, 403-408.	0.5	94
653	Progression of chronic kidney disease: insights from animal models. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 250-257.	2.1	45
654	Prevention programmes of progressive renal disease in developing nations (Review Article). <i>Nephrology</i> , 2006, 11, 321-328.	1.7	53
655	Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. <i>Experimental Dermatology</i> , 2006, 15, 958-965.	3.0	29
656	ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. <i>Kidney International</i> , 2006, 69, 1124-1130.	5.6	107
657	Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. <i>Kidney International</i> , 2006, 69, 1675-1682.	5.6	92
658	Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. <i>Kidney International</i> , 2006, 69, 2057-2063.	5.6	423
659	Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. <i>Kidney International</i> , 2006, 70, 97-103.	5.6	71
660	A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. <i>Kidney International</i> , 2006, 70, 423-431.	5.6	241
661	Time to abandon microalbuminuria?. <i>Kidney International</i> , 2006, 70, 1214-1222.	5.6	184
662	Meeting report on the Bellagio Conference "prevention of vascular diseases in the emerging world: An approach to global health equity". <i>Kidney International</i> , 2006, 70, 1397-1402.	5.6	15
663	Biocompatibility and function of microencapsulated pancreatic islets. <i>Acta Biomaterialia</i> , 2006, 2, 221-227.	8.8	45
664	Long-Term Renal Allograft Function on a Tacrolimus-Based, Pred-Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF+.. <i>American Journal of Transplantation</i> , 2006, 6, 1617-1623.	5.0	70
665	Favorable Long-Term Outcome after Liver-Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation. <i>American Journal of Transplantation</i> , 2006, 6, 1948-1952.	5.0	110
666	Ways to Boost Kidney Transplant Viability: A Real Need for the Best Use of Older Donors. <i>American Journal of Transplantation</i> , 2006, 6, 2543-2547.	5.0	37

#	ARTICLE	IF	CITATIONS
667	Timed Urine Collections Are Not Needed to Measure Urine Protein Excretion in Clinical Practice. American Journal of Kidney Diseases, 2006, 47, 1-7.	2.0	82
668	Thrombotic Thrombocytopenic Purpura-Then and Now. Seminars in Thrombosis and Hemostasis, 2006, 32, 081-089.	2.8	52
669	Long-Term Outcome of Renal Transplantation from Older Donors. New England Journal of Medicine, 2006, 354, 343-352.	30.7	456
670	Complement Factor H Gene Abnormalities in Haemolytic Uraemic Syndrome: From Point Mutations to Hybrid Gene. PLoS Medicine, 2006, 3, e432.	8.5	6
671	Computed Tomography Evaluation of Autosomal Dominant Polycystic Kidney Disease Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 754-760.	4.6	38
672	Basiliximab Combined with Low-Dose Rabbit Anti-Human Thymocyte Globulin: A Possible Further Step toward Effective and Minimally Toxic T Cell-Targeted Therapy in Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 546-554.	4.6	44
673	Correction of Anemia - Payoffs and Problems. New England Journal of Medicine, 2006, 355, 2144-2146.	30.7	51
674	Immunophenotypic Analysis of Cellular Infiltrate of Renal Allograft Biopsies in Patients with Acute Rejection after Induction with Alemtuzumab (Campath-1H). Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 539-545.	4.6	27
675	Review: Potential protective effects of telmisartan on renal function deterioration. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 185-191.	1.7	13
676	Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. Journal of Clinical Investigation, 2006, 116, 288-296.	6.7	516
677	Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 761-767.	4.6	176
678	Beneficial Effect of TGF β 2 Antagonism in Treating Diabetic Nephropathy Depends on When Treatment Is Started. Nephron Experimental Nephrology, 2006, 104, e158-e168.	2.3	43
679	Rituximab for Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 738-748.	4.6	84
680	Outcome of Renal Transplantation in Patients with Non-Shiga Toxin-Associated Hemolytic Uremic Syndrome: Prognostic Significance of Genetic Background. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 88-99.	4.6	206
681	Non-Shiga toxin-associated hemolytic uremic syndrome. , 2006, , 65-83.		6
682	The hemolytic uremic syndromes. Current Opinion in Critical Care, 2005, 11, 487-492.	3.5	35
683	Dendritic Cells Genetically Engineered with Adenoviral Vector Encoding dnIKK2 Induce the Formation of Potent CD4+ T-Regulatory Cells. Transplantation, 2005, 79, 1056-1061.	1.1	33
684	Effect of a Novel Immunosuppressant, ST1959, on the Immune System and Renal Allograft Survival in Rats. Transplantation, 2005, 80, 231-236.	1.1	2

#	ARTICLE	IF	CITATIONS
685	Cyclosporine Formulation and Kaposi's Sarcoma after Renal Transplantation. <i>Transplantation</i> , 2005, 80, 743-748.	1.1	14
686	Pretransplant Donor Peripheral Blood Mononuclear Cells Infusion Induces Transplantation Tolerance by Generating Regulatory T Cells. <i>Transplantation</i> , 2005, 79, 1034-1039.	1.1	27
687	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. <i>Blood</i> , 2005, 106, 1262-1267.	1.4	278
688	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. <i>Blood</i> , 2005, 106, 925-928.	1.4	57
689	Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. <i>Blood</i> , 2005, 106, 1932-1937.	1.4	291
690	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 95-105.	0.2	4
691	High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 816, 99-105.	2.4	31
692	Subcutaneous xenotransplantation of bovine pancreatic islets. <i>Biomaterials</i> , 2005, 26, 5640-5647.	11.8	25
693	Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. <i>Kidney International</i> , 2005, 67, 1753-1761.	5.6	126
694	Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. <i>Kidney International</i> , 2005, 68, 206-216.	5.6	239
695	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. <i>Kidney International</i> , 2005, 67, S2-S7.	5.6	55
696	The scientific care for prevention: An overview. <i>Kidney International</i> , 2005, 67, S8-S13.	5.6	3
697	Pathophysiology of disease progression in proteinuric nephropathies. <i>Kidney International</i> , 2005, 67, S79-S82.	5.6	24
698	Kidney prevention recipes for your office practice. <i>Kidney International</i> , 2005, 67, S136-S141.	5.6	5
699	Strategies for national health care systems in emerging countries: The case of screening and prevention of renal disease progression in Bolivia. <i>Kidney International</i> , 2005, 68, S87-S94.	5.6	46
700	The future of renoprotection. <i>Kidney International</i> , 2005, 68, S95-S101.	5.6	18
701	Prevention of chronic kidney and vascular disease: Toward global health equity? The Bellagio 2004 Declaration. <i>Kidney International</i> , 2005, 68, S1-S6.	5.6	87
702	Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications. <i>Kidney International</i> , 2005, 68, S7-S10.	5.6	301

#	ARTICLE	IF	CITATIONS
703	Prevention of progression and remission/regression strategies for chronic renal diseases: Can we do better now than five years ago?. <i>Kidney International</i> , 2005, 68, S21-S24.	5.6	17
704	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. <i>Kidney International</i> , 2005, 68, S57-S65.	5.6	388
705	Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation. <i>Xenotransplantation</i> , 2005, 12, 110-120.	3.0	14
706	Generic cyclosporine formulations: more open questions than answers. <i>Transplant International</i> , 2005, 18, 371-378.	1.8	29
707	Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation. <i>American Journal of Transplantation</i> , 2005, 5, 1146-1150.	5.0	118
708	Assessing Renal Function by GFR Prediction Equations in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1175-1176.	5.0	19
709	Autologous Stem Cell and Kidney Transplantation for Primary Amyloidosis Associated with ESRD: Which Should Come First?. <i>American Journal of Transplantation</i> , 2005, 5, 1585-1586.	5.0	7
710	Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 2937-2944.	5.0	74
711	Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?. <i>Nature Clinical Practice Nephrology</i> , 2005, 1, 2-3.	1.0	19
712	Dual Blockade of the Renin-Angiotensin System. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S34-S38.	0.5	24
713	Is Regression of Chronic Nephropathies a Therapeutic Target?. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 840-842.	0.5	8
714	Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S58-S63.	0.5	75
715	Cyclosporine Prolongs Delayed Graft Function in Kidney Transplantation: Are Rabbit Anti-Human Thymocyte Globulins the Answer?. <i>Nephron Clinical Practice</i> , 2005, 101, c65-c71.	2.1	23
716	Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1741-1744.	0.8	24
717	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. <i>Lancet, The</i> , 2005, 365, 939-946.	12.2	598
718	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. <i>Thrombosis and Haemostasis</i> , 2005, 93, 443-452.	3.5	81
719	Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. , 2005, 15, 71-76.		16
720	Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1931-1942.	1.9	5

#	ARTICLE	IF	CITATIONS
721	Emerging drugs for diabetic nephropathy. Expert Opinion on Emerging Drugs, 2005, 10, 747-771.	2.5	9
722	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: Not simply overestimation. Clinica Chimica Acta, 2005, 355, 153-164.	1.6	17
723	Binding of Complement Factor H to Endothelial Cells Is Mediated by the Carboxy-Terminal Glycosaminoglycan Binding Site. American Journal of Pathology, 2005, 167, 1173-1181.	4.2	108
724	In Response to Protein Load Podocytes Reorganize Cytoskeleton and Modulate Endothelin-1 Gene. American Journal of Pathology, 2005, 166, 1309-1320.	4.2	152
725	Blood Cyclosporine Level Soon After Kidney Transplantation is a Major Determinant of Rejection: Insights From the Mycophenolate Steroid-Sparing Trial. Transplantation Proceedings, 2005, 37, 2037-2040.	0.6	8
726	Rationaleâ€”Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal, 2005, 149, 408-413.	3.1	115
727	Mechanisms of Disease: pre-eclampsia. Nature Clinical Practice Nephrology, 2005, 1, 98-114.	1.0	262
728	Albuminuria as early test for vascular disease. Lancet, The, 2005, 365, 556-557.	12.2	27
729	Albuminuria as early test for vascular disease. Lancet, The, 2005, 365, 556-557.	12.2	42
730	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy: Open Access in Clinical Medicine, 2005, 2, 95-105.	0.2	1
731	Hyperuricemia in Kidney Transplantation. , 2004, 147, 124-131.		25
732	Genetics of rare diseases of the kidney: learning from mouse models. Cytogenetic and Genome Research, 2004, 105, 479-484.	0.9	5
733	Platelet Dysfunction in Renal Failure. Seminars in Thrombosis and Hemostasis, 2004, 30, 579-589.	2.8	401
734	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. Expert Opinion on Therapeutic Patents, 2004, 14, 1553-1566.	5.2	5
735	Nitric Oxide Synthetic Capacity in Relation to Dialysate Temperature. Blood Purification, 2004, 22, 203-209.	1.9	22
736	Favorable Effect of Cotransfection with TGF- β 2 and CTLA4Ig of the Donor Kidney on Allograft Survival. American Journal of Nephrology, 2004, 24, 275-283.	3.2	12
737	Preventing Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2004, 351, 1941-1951.	30.7	956
738	Insulin Resistance and Proliferative Retinopathy: A Cross-Sectional, Case-Control Study in 115 Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4371-4376.	3.7	42

#	ARTICLE	IF	CITATIONS
739	In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. <i>Kidney International</i> , 2004, 65, 1084-1090.	5.6	24
740	Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. <i>Kidney International</i> , 2004, 65, 2193-2200.	5.6	112
741	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. <i>Kidney International</i> , 2004, 65, 2309-2320.	5.6	848
742	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. <i>Kidney International</i> , 2004, 66, 1959-1965.	5.6	53
743	Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN). <i>Kidney International</i> , 2004, 66, S90-S96.	5.6	64
744	From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy. <i>American Journal of Transplantation</i> , 2004, 4, 299-310.	5.0	58
745	Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing. <i>American Journal of Transplantation</i> , 2004, 4, 1345-1351.	5.0	59
746	Performance of Different Prediction Equations for Estimating Renal Function in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 1826-1835.	5.0	184
747	The potential of endothelin antagonism as a therapeutic approach. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1419-1435.	4.2	12
748	<scp>l</scp> -Arginine Depletion in Preeclampsia Orients Nitric Oxide Synthase Toward Oxidant Species. <i>Hypertension</i> , 2004, 43, 614-622.	5.0	140
749	Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy. <i>Circulation</i> , 2004, 110, 921-927.	5.0	688
750	Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. <i>Seminars in Nephrology</i> , 2004, 24, 131-140.	1.6	44
751	Losartan in diabetic nephropathy. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 473-483.	1.6	16
752	Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. <i>American Journal of Kidney Diseases</i> , 2004, 44, 385-401.	2.0	97
753	Nephrotoxic aspects of cyclosporine. <i>Transplantation Proceedings</i> , 2004, 36, S234-S239.	0.6	68
754	Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. <i>Lancet, The</i> , 2004, 364, 503-512.	12.2	156
755	Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. <i>Lancet, The</i> , 2004, 364, 513-520.	12.2	342
756	Novel methods for disinfection of prion-contaminated medical devices. <i>Lancet, The</i> , 2004, 364, 521-526.	12.2	242

#	ARTICLE	IF	CITATIONS
757	Independent clinical research in Europe. <i>Lancet, The</i> , 2004, 364, 1723-1726.	12.2	24
758	Delayed graft function in kidney transplantation. <i>Lancet, The</i> , 2004, 364, 1814-1827.	12.2	848
759	A COMPARATIVE PROSPECTIVE STUDY OF TWO AVAILABLE SOLUTIONS FOR KIDNEY AND LIVER PRESERVATION. <i>Transplantation</i> , 2004, 77, 1540-1545.	1.1	58
760	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. <i>Personalized Medicine</i> , 2004, 1, 53-62.	1.4	1
761	Cellular responses to protein overload: key event in renal disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 31-37.	2.1	132
762	Proteinuria in diabetic nephropathy: Treatment and evolution. <i>Current Diabetes Reports</i> , 2003, 3, 497-504.	4.4	29
763	Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?. <i>Current Hypertension Reports</i> , 2003, 5, 364-367.	3.4	2
764	Adult nondiarrhea hemolytic uremic syndrome associated with shiga toxin escherichia coli O157:H7 bacteremia and urinary tract infection. <i>American Journal of Kidney Diseases</i> , 2003, 41, e4.1-e4.4.	2.0	34
765	Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. <i>Kidney International</i> , 2003, 63, 2254-2261.	5.6	245
766	Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. <i>Kidney International</i> , 2003, 64, 857-863.	5.6	13
767	ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. <i>Kidney International</i> , 2003, 64, 2253-2261.	5.6	31
768	The future of renoprotection: Frustration and promises. <i>Kidney International</i> , 2003, 64, 1947-1955.	5.6	47
769	Renoprotection: Clues from knockout models of rare diseases. <i>Kidney International</i> , 2003, 63, 764-766.	5.6	7
770	Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. <i>Kidney International</i> , 2003, 63, 1094-1103.	5.6	168
771	Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. <i>Kidney International</i> , 2003, 63, 1924-1933.	5.6	10
772	Preventing end-stage renal disease: The potential impact of screening and intervention in developing countries. <i>Kidney International</i> , 2003, 63, 1948-1950.	5.6	21
773	Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 632-634.	4.1	52
774	Familial haemolytic uraemic syndrome and an MCP mutation. <i>Lancet, The</i> , 2003, 362, 1542-1547.	12.2	307

#	ARTICLE	IF	CITATIONS
775	Nonimmunosuppressive therapy of membranous nephropathy. <i>Seminars in Nephrology</i> , 2003, 23, 333-339.	1.6	19
776	Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies. <i>Circulation</i> , 2003, 107, 586-592.	5.0	65
777	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. <i>Human Molecular Genetics</i> , 2003, 12, 3385-3395.	3.0	291
778	Can We Really Lessen Kidney Damage to the Point that the Loss of Renal Function of Progressive Nephropathy May Revert?. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1411-1414.	0.5	5
779	Chronic Nephropathies: Individual Risk for Progression to End-Stage Renal Failure as Predicted by an Integrated Probabilistic Model. <i>Nephron Clinical Practice</i> , 2003, 95, c47-c59.	2.1	6
780	Renal Transplantation: Can We Reduce Calcineurin Inhibitor/Stop Steroids? Evidence Based on Protocol Biopsy Findings. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 755-766.	0.5	27
781	Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 858-859.	0.8	24
782	Rituximab in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1851-1857.	0.5	209
783	Add-On Anti-TGF- β Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1816-1824.	0.5	177
784	The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2047-2053.	0.8	145
785	Radial Artery Remodeling in Response to Shear Stress Increase Within Arteriovenous Fistula for Hemodialysis Access. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2003, 10, 95-102.	1.6	72
786	Antihypertensive therapy in chronic renal disease. <i>Journal of Hypertension</i> , 2003, 21, 1625-1626.	0.5	2
787	DOPPLER ULTRASONOGRAPHY IN POSTTRANSPLANT RENAL ARTERY STENOSIS. <i>Transplantation</i> , 2003, 76, 147-153.	1.1	43
788	Tackling the Shortage of Donor Kidneys: How to Use the Best that We Have. <i>American Journal of Nephrology</i> , 2003, 23, 245-259.	3.2	81
789	Targeted Downregulation of Extracellular Nephritin in Human IgA Nephropathy. <i>American Journal of Nephrology</i> , 2003, 23, 277-286.	3.2	41
790	Proteinuria and its consequences in renal disease. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2003, 92, 9-13.	1.6	19
791	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. <i>Journal of Clinical Investigation</i> , 2003, 111, 1181-1190.	6.7	317
792	Halting the Progression of Chronic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, S190-S195.	0.5	43

#	ARTICLE	IF	CITATIONS
793	Hyperhomocysteinemia and Increased Risk of Retinopathy: A cross-sectional, case-control study in patients with type 2 diabetes. <i>Diabetes Care</i> , 2002, 25, 2361-2361.	9.3	8
794	How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2898-2908.	0.5	156
795	Routine renin-angiotensin system blockade in renal transplantation?. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 1-10.	2.1	22
796	Chronic Renal Diseases: Renoprotective Benefits of Renin-Angiotensin System Inhibition. <i>Annals of Internal Medicine</i> , 2002, 136, 604.	9.7	238
797	Lymphomas occurring late after solid-organ transplantation. <i>Transplantation</i> , 2002, 74, 1095-1102.	1.1	130
798	Nitric oxide and renal perfusion in humans. <i>Journal of Hypertension</i> , 2002, 20, 391-393.	0.5	2
799	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. <i>Blood</i> , 2002, 100, 778-785.	1.4	200
800	Factor H family proteins: on complement, microbes and human diseases. <i>Biochemical Society Transactions</i> , 2002, 30, 971-978.	3.5	244
801	Transforming Growth Factor- β 1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins. <i>American Journal of Pathology</i> , 2002, 161, 2179-2193.	4.2	138
802	Nephropathy in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2002, 346, 1145-1151.	30.7	539
803	Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. <i>Lancet, The</i> , 2002, 359, 663-666.	12.2	112
804	Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. <i>Lancet, The</i> , 2002, 359, 1671-1672.	12.2	154
805	Tacrolimus and ciclosporin microemulsion in renal transplantation. <i>Lancet, The</i> , 2002, 360, 799-800.	12.2	6
806	Rituximab for idiopathic membranous nephropathy. <i>Lancet, The</i> , 2002, 360, 923-924.	12.2	321
807	One or two marginal organs for kidney transplantation?. <i>Transplantation Proceedings</i> , 2002, 34, 3091-3096.	0.6	9
808	Xenotransplantation in the 21st Century. <i>Blood Purification</i> , 2002, 20, 45-54.	1.9	10
809	Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. <i>American Journal of Kidney Diseases</i> , 2002, 40, 783-793.	2.0	68
810	Conflict of interest as seen from a researcher's perspective. <i>Science and Engineering Ethics</i> , 2002, 8, 337-342.	3.1	4

#	ARTICLE	IF	CITATIONS
811	Propionyl-l-carnitine prevents renal function deterioration due to ischemia/reperfusion. <i>Kidney International</i> , 2002, 61, 1064-1078.	5.6	62
812	ACE inhibitors and AT1 receptor antagonists: Is two better than one?. <i>Kidney International</i> , 2002, 61, 1545-1547.	5.6	12
813	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. <i>Kidney International</i> , 2002, 61, 1635-1645.	5.6	103
814	Proximal tubular cells promote fibrogenesis by TGF- β 1-mediated induction of peritubular myofibroblasts. <i>Kidney International</i> , 2002, 61, 2066-2077.	5.6	109
815	Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF- κ B dependent up-regulation of IL-8 and MCP-11. <i>Kidney International</i> , 2002, 62, 846-856.	5.6	107
816	Effect of angiotensin II antagonism on the regression of kidney disease in the rat. <i>Kidney International</i> , 2002, 62, 885-894.	5.6	76
817	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. <i>Kidney International</i> , 2002, 62, 1060-1067.	5.6	215
818	Effect of high dose ramipril with or without indomethacin on glomerular selectivity. <i>Kidney International</i> , 2002, 62, 1010-1019.	5.6	23
819	Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. <i>Kidney International</i> , 2002, 61, S115-S119.	5.6	10
820	New therapeutics that antagonize endothelin: promises and frustrations. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 986-1001.	56.6	131
821	Platelets and renal diseases. , 2002, , 837-851.		0
822	Drug-Induced Thrombotic Microangiopathy. <i>Drug Safety</i> , 2001, 24, 491-501.	3.3	114
823	Renoprotective Therapy in Patients With Nondiabetic Nephropathies. <i>Drugs</i> , 2001, 61, 733-745.	11.2	18
824	Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. <i>Annals of Internal Medicine</i> , 2001, 135, 73.	9.7	942
825	Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2001, 345, 861-869.	30.7	6,691
826	Automatic Generation of Glomerular Capillary Topological Organization. <i>Microvascular Research</i> , 2001, 62, 346-354.	2.6	24
827	Angiotensin-Converting Enzyme inhibition Prevents Glomerular-Tubule Disconnection and Atrophy in Passive Heymann Nephritis, an Effect Not Observed with a Calcium Antagonist. <i>American Journal of Pathology</i> , 2001, 159, 1743-1750.	4.2	45
828	Complement factor H and hemolytic uremic syndrome. <i>International Immunopharmacology</i> , 2001, 1, 461-468.	3.9	27

#	ARTICLE	IF	CITATIONS
829	How renal cytokines and growth factors contribute to renal disease progression. American Journal of Kidney Diseases, 2001, 37, S21-S24.	2.0	57
830	Optimization of cyclosporine therapy in the neoral era: abbreviated AUC, single blood sampling?. Transplantation Proceedings, 2001, 33, 3117-3119.	0.6	11
831	Progression, remission, regression of chronic renal diseases. Lancet, The, 2001, 357, 1601-1608.	12.2	495
832	The uses of error: diagnostic preferences. Lancet, The, 2001, 358, 1005.	12.2	0
833	Modulating the profit motive to meet needs of the less-developed world. Lancet, The, 2001, 358, 1638-1641.	12.2	20
834	Familial and Recurrent Forms of Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 2001, 136, 125-139.		4
835	Renin-Angiotensin System, Proteinuria, and Tubulointerstitial Damage. , 2001, 135, 187-199.		3
836	Gene Therapy to the Kidney. , 2001, 136, 140-156.		1
837	Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein Excretion. Nephron, 2001, 88, 254-259.	1.8	34
838	Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. Clinical Chemistry, 2001, 47, 1679-1687.	3.5	56
839	Thrombotic Microangiopathies in the Intensive Care Unit: Many Questions, Some Answers. , 2001, 132, 53-67.		2
840	Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Current Opinion in Nephrology and Hypertension, 2001, 10, 1-6.	2.1	23
841	Verotoxin-1/induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood, 2001, 98, 1828-1835.	1.4	94
842	Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International, 2001, 59, 286-294.	5.6	42
843	Post-transplant renal artery stenosis: The hemodynamic response to revascularization. Kidney International, 2001, 60, 309-318.	5.6	31
844	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney International, 2001, 60, 653-663.	5.6	50
845	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney International, 2001, 60, 1131-1140.	5.6	336
846	Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney International, 2001, 60, 831-846.	5.6	407

#	ARTICLE	IF	CITATIONS
847	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. <i>Clinical Transplantation</i> , 2001, 15, 402-409.	1.7	75
848	Novel mechanism(s) implicated in tubular albumin reabsorption and handling. <i>American Journal of Kidney Diseases</i> , 2001, 38, 196-200.	2.0	11
849	Challenges to achieving clinical transplantation tolerance. <i>Journal of Clinical Investigation</i> , 2001, 108, 943-948.	6.7	103
850	Computational Fluid Dynamics of a Vascular Access Case for Hemodialysis. <i>Journal of Biomechanical Engineering</i> , 2001, 123, 284-292.	1.4	59
851	Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 282-305.	2.6	68
852	IMMUNOMODULATION BY INTRATHYMIC INJECTION OF DONOR LEUKOCYTES IN RHESUS MONKEYS1. <i>Transplantation</i> , 2001, 72, 1432-1436.	1.1	7
853	Thymic Microchimerism Correlates with the Outcome of Tolerance-Inducing Protocols for Solid Organ Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2815-2826.	0.5	25
854	The Molecular Basis of Familial Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 297-307.	0.5	265
855	Blocking Angiotensin II Synthesis/Activity Preserves Glomerular Nephron in Rats with Severe Nephrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 941-948.	0.5	123
856	Combined Treatment with Mycophenolate Mofetil and an Angiotensin II Receptor Antagonist Fully Protects from Chronic Rejection in a Rat Model of Renal Allograft. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1937-1946.	0.5	32
857	Molecular Medicine in Organ Transplantation: How and When?. , 2001, , 317-334.		0
858	Pharmacologic Monitoring of Immunosuppressive Drugs. , 2001, , 43-59.		0
859	Challenges to achieving clinical transplantation tolerance. <i>Journal of Clinical Investigation</i> , 2001, 108, 943-948.	6.7	44
860	Effect of Cigarette Smoking on Renal Function and Vascular Endothelium. , 2000, 130, 45-52.		9
861	Thymic Dendritic Cells Express Inducible Nitric Oxide Synthase and Generate Nitric Oxide in Response to Self- and Alloantigens. <i>Journal of Immunology</i> , 2000, 164, 4649-4658.	0.8	64
862	RISK OF NONMELANOMA SKIN CANCER IN ITALIAN ORGAN TRANSPLANT RECIPIENTS. A REGISTRY-BASED STUDY. <i>Transplantation</i> , 2000, 70, 1479-1484.	1.1	104
863	A unifying hypothesis for renal scarring linking protein trafficking to the different mediators of injury. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 58-60.	0.8	13
864	Repairing renal lesions: Will VEGF be the builder?. <i>Kidney International</i> , 2000, 58, 2594-2595.	5.6	12

#	ARTICLE	IF	CITATIONS
865	ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. <i>Kidney International</i> , 2000, 57, 274-281.	5.6	76
866	Pretreatment blood pressure reliably predicts progression of chronic nephropathies. <i>Kidney International</i> , 2000, 58, 2093-2101.	5.6	10
867	Nonviral and Viral Gene Transfer to the Kidney in the Context of Transplantation. <i>Nephron</i> , 2000, 85, 307-316.	1.8	14
868	17 β -Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 279, F626-F635.	3.0	25
869	Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1900-1902.	0.8	70
870	Strategies for Making More Organs Available for Transplantation. <i>New England Journal of Medicine</i> , 2000, 343, 404-410.	30.7	263
871	Prostacyclin and Thromboxane and the Development of Preeclampsia. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 1568.	7.1	2
872	Shear Stress-Induced Cytoskeleton Rearrangement Mediates NF- κ B-Dependent Endothelial Expression of ICAM-1. <i>Microvascular Research</i> , 2000, 60, 182-188.	2.6	29
873	Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. <i>American Journal of Kidney Diseases</i> , 2000, 35, 1155-1165.	2.0	175
874	ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. <i>American Journal of Kidney Diseases</i> , 2000, 35, 381-391.	2.0	71
875	A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. <i>American Journal of Kidney Diseases</i> , 2000, 36, 695-702.	2.0	14
876	Hemolytic uremic syndrome: Past and present. <i>American Journal of Kidney Diseases</i> , 2000, 36, liv-lvi.	2.0	5
877	Protein traffic activates NF- κ B gene signaling and promotes MCP-1-dependent interstitial inflammation. <i>American Journal of Kidney Diseases</i> , 2000, 36, 1226-1241.	2.0	146
878	Fluid loading: Neither safe nor efficacious in the treatment of the alcohol-intoxicated patient in the ED. <i>American Journal of Emergency Medicine</i> , 2000, 18, 121.	1.8	1
879	The Role of Protein Traffic in the Progression of Renal Diseases. <i>Annual Review of Medicine</i> , 2000, 51, 315-327.	12.5	65
880	Endothelin Antagonists and Renal Protection. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, S75-S78.	1.9	27
881	EPSTEIN-BARR VIRUS-NEGATIVE LYMPHOPROLIFERATIVE DISORDERS IN LONG-TERM SURVIVORS AFTER HEART, KIDNEY, AND LIVER TRANSPLANT1. <i>Transplantation</i> , 2000, 69, 827-833.	1.1	146
882	RENAL TRANSPLANTATION: SINGLE OR DUAL FOR DONORS AGING ???60 YEARS?. <i>Transplantation</i> , 2000, 69, 2000-2001.	1.1	27

#	ARTICLE	IF	CITATIONS
883	Chronic Proteinuric Nephropathies. II. Outcomes and Response to Treatment in a Prospective Cohort of 352 Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 88-96.	0.5	92
884	Effect of Angiotensin-Converting Enzyme Inhibition on Glomerular Basement Membrane Permeability and Distribution of Zonula Occludens-1 in MWF Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 477-489.	0.5	115
885	CTLA4lg Gene Transfer Prolongs Survival and Induces Donor-Specific Tolerance in a Rat Renal Allograft. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 747-752.	0.5	64
886	Nephropathy in NIDDM Patients, Predictors of Outcome. , 2000, , 237-246.		1
887	Prostacyclin and Thromboxane and the Development of Preeclampsia. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 1568-1569.	7.1	0
888	Nitric Oxide/L-Arginine in Uremia. <i>Mineral and Electrolyte Metabolism</i> , 1999, 25, 384-390.	1.1	20
889	ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, F457-F466.	3.0	41
890	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. <i>Blood</i> , 1999, 94, 610-620.	1.4	44
891	Uremic Bleeding: Closing the Circle After 30 Years of Controversies?. <i>Blood</i> , 1999, 94, 2569-2574.	1.4	194
892	Sympathetic Overactivity in Hypertensive Patients with Chronic Renal Disease. <i>New England Journal of Medicine</i> , 1999, 340, 1360-1361.	30.7	29
893	Proteinuria as a Mediator of Tubulointerstitial Injury. <i>Kidney and Blood Pressure Research</i> , 1999, 22, 37-46.	2.0	46
894	Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. <i>Kidney International</i> , 1999, 55, 674-685.	5.6	93
895	Peripheral donor leukocytes prolong survival of rat renal allografts. <i>Kidney International</i> , 1999, 56, 1101-1112.	5.6	34
896	IgA nephropathy: A stem cell disease?. <i>Kidney International</i> , 1999, 56, 1964-1966.	5.6	8
897	Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. <i>Kidney International</i> , 1999, 55, 984-994.	5.6	51
898	Protein Overload Activates Proximal Tubular Cells to Release Vasoactive and Inflammatory Mediators. <i>Nephron Experimental Nephrology</i> , 1999, 7, 420-428.	2.3	56
899	ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. <i>American Journal of Kidney Diseases</i> , 1999, 34, 626-632.	2.0	62
900	Renoprotective effect of ACE inhibitors: Dissecting the molecular clues and expanding the blood pressure goal. <i>American Journal of Kidney Diseases</i> , 1999, 34, 951-954.	2.0	11

#	ARTICLE	IF	CITATIONS
901	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. American Journal of Kidney Diseases, 1999, 33, 746-753.	2.0	42
902	Cigarette smoking and renal function impairment. American Journal of Kidney Diseases, 1999, 33, 807-810.	2.0	40
903	Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. American Journal of Kidney Diseases, 1999, 33, 267-275.	2.0	34
904	Endothelin antagonists. Lancet, The, 1999, 353, 133-138.	12.2	240
905	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, The, 1999, 354, 359-364.	12.2	809
906	Lessons from the Di Bella affair. Lancet, The, 1999, 353, 1289-1290.	12.2	21
907	Transplant tolerance: facts and future. Transplantation Proceedings, 1999, 31, 2955-2957.	0.6	2
908	Double transplant of marginal kidneys. Transplantation Proceedings, 1999, 31, 2962-2964.	0.6	0
909	Nephrotoxicity of increased glomerular protein traffic. Nephrology Dialysis Transplantation, 1999, 14, 304-312.	0.8	53
910	Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases. Annals of Internal Medicine, 1999, 130, 422.	9.7	129
911	Physiology and Pathophysiology of Nitric Oxide in Chronic Renal Disease. Proceedings of the Association of American Physicians, 1999, 111, 602-610.	2.4	40
912	Nephropathic nature of proteinuria. Current Opinion in Nephrology and Hypertension, 1999, 8, 655-663.	2.1	59
913	Genes and molecular medicine in the future of organ transplantation. Current Opinion in Organ Transplantation, 1999, 4, 65.	1.6	4
914	Xenogeneic Serum Promotes Leukocyte-Endothelium Interaction under Flow through Two Temporally Distinct Pathways. Journal of the American Society of Nephrology: JASN, 1999, 10, 2197-2207.	0.5	20
915	Early Experience with Dual Kidney Transplantation in Adults using Expanded Donor Criteria. Journal of the American Society of Nephrology: JASN, 1999, 10, 2591-2598.	0.5	339
916	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	1
917	Are HUS and TTP genetically determined?. Kidney International, 1998, 53, 1085-1086.	5.6	7
918	Xenogeneic human serum promotes leukocyte adhesion to porcine endothelium under flow conditions, possibly through the activation of the transcription factor NF- κ B. Xenotransplantation, 1998, 5, 57-60.	3.0	12

#	ARTICLE	IF	CITATIONS
919	Assessment of glomerular size-selective function with fractional clearance of neutral dextran. <i>Translational Research</i> , 1998, 132, 360-362.	2.4	4
920	Hemostasis in renal failure. <i>Intensivmedizin Und Notfallmedizin</i> , 1998, 35, 382-389.	0.1	0
921	Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy ¹ . <i>Kidney International</i> , 1998, 54, 353-359.	5.6	78
922	Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with $\hat{I}\pm 3$ chain of type IV collagen. <i>Kidney International</i> , 1998, 54, 1550-1561.	5.6	44
923	Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. <i>Kidney International</i> , 1998, 54, 2146-2150.	5.6	26
924	Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. <i>Kidney International</i> , 1998, 53, 726-734.	5.6	73
925	Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. <i>Kidney International</i> , 1998, 53, 1209-1216.	5.6	382
926	Protein overload stimulates RANTES production by proximal tubular cells depending on NF- κ B activation. <i>Kidney International</i> , 1998, 53, 1608-1615.	5.6	374
927	Prognosis of diabetic nephropathy: how to improve the outcome. <i>Diabetes Research and Clinical Practice</i> , 1998, 39, S49-S53.	2.9	8
928	Transplant tolerance: will genes protect the graft?. <i>Lancet, The</i> , 1998, 351, 1749-1751.	12.2	8
929	Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. <i>Lancet, The</i> , 1998, 352, 1252-1256.	12.2	524
930	Reducing mortality and increasing awareness. <i>Lancet, The</i> , 1998, 352, S20.	12.2	1
931	Cellular basis of long-term organ transplant acceptance: Pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. <i>American Journal of Kidney Diseases</i> , 1998, 31, 197-212.	2.0	35
932	Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF- β in experimental mesangioproliferative glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 1998, 31, 453-463.	2.0	55
933	Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: Implications for dialysis hypotension. <i>American Journal of Kidney Diseases</i> , 1998, 32, 115-124.	2.0	81
934	Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients. <i>Transplantation Proceedings</i> , 1998, 30, 1654-1655.	0.6	1
935	Optimization of cyclosporine therapy in kidney transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 1673-1676.	0.6	1
936	Pathophysiology of Progressive Nephropathies. <i>New England Journal of Medicine</i> , 1998, 339, 1448-1456.	30.7	1,145

#	ARTICLE	IF	CITATIONS
937	Identification of a Novel Gene "SSK1" in Human Endothelial Cells Exposed to Shear Stress. <i>Biochemical and Biophysical Research Communications</i> , 1998, 246, 881-887.	2.2	6
938	von Willebrand Factor "Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic" Uremic Syndrome. <i>New England Journal of Medicine</i> , 1998, 339, 1578-1584.	30.7	1,730
939	Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. <i>BMJ: British Medical Journal</i> , 1998, 316, 504-509.	5.7	224
940	Novel strategies to retard renal disease progression: combining ACE inhibition with endothelin receptor blocking?. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 2734-2738.	0.8	9
941	Angiotensin II Blockade Limits Tubular Protein Overreabsorption and the Consequent Upregulation of Endothelin 1 Gene in Experimental Membranous Nephropathy. <i>Nephron Experimental Nephrology</i> , 1998, 6, 121-131.	2.3	44
942	Prevention of Renal Injury in Diabetic MWF Rats by Angiotensin II Antagonism. <i>Nephron Experimental Nephrology</i> , 1998, 6, 28-38.	2.3	41
943	Renal epidemiology. The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 3034-3036.	0.8	54
944	Application of newer clearance techniques for the determination of glomerular filtration rate. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 675-680.	2.1	76
945	Endothelin receptor antagonists: which are the therapeutic perspectives in renal diseases?. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 5-7.	0.8	18
946	Angiotensin II receptor antagonists and treatment of hypertension and renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 571-578.	2.1	16
947	Cyclosporine/tacrolimus (FK-506). , 1998, , 275-300.		2
948	Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF- κ B-dependent fashion.. <i>Journal of Clinical Investigation</i> , 1998, 101, 1905-1915.	6.7	382
949	The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 2308-2317.	0.5	64
950	The renoprotective potential of endothelin receptor antagonists. <i>Expert Opinion on Therapeutic Patents</i> , 1997, 7, 139-149.	5.2	11
951	Nonviral Gene Delivery to the Rat Kidney with Polyethylenimine. <i>Human Gene Therapy</i> , 1997, 8, 1243-1251.	3.0	188
952	Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 1997, 6, 489-495.	2.1	34
953	The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. <i>Current Opinion in Nephrology and Hypertension</i> , 1997, 6, 141-145.	2.1	18
954	Recent developments in the management of membranous nephropathy. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 521-532.	4.2	7

#	ARTICLE	IF	CITATIONS
955	Prevention of Transplant Rejection. <i>Drugs</i> , 1997, 54, 533-570.	11.2	80
956	Dearingâ€™a report to be embraced. <i>Lancet, The</i> , 1997, 350, 308.	12.2	4
957	The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. <i>American Journal of Kidney Diseases</i> , 1997, 29, 254-264.	2.0	74
958	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. <i>Blood</i> , 1997, 90, 1558-1564.	1.4	124
959	Understanding the nature of renal disease progression. <i>Kidney International</i> , 1997, 51, 2-15.	5.6	574
960	Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. <i>Kidney International</i> , 1997, 51, 1583-1589.	5.6	134
961	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. <i>Kidney International</i> , 1997, 52, 171-181.	5.6	138
962	Acquired transplant tolerance. <i>International Journal of Clinical and Laboratory Research</i> , 1997, 27, 165-177.	0.9	16
963	SEQUENTIAL MONITORING OF URINE-SOLUBLE INTERLEUKIN 2 RECEPTOR AND INTERLEUKIN 6 PREDICTS ACUTE REJECTION OF HUMAN RENAL ALLOGRAFTS BEFORE CLINICAL OR LABORATORY SIGNS OF RENAL DYSFUNCTION. <i>Transplantation</i> , 1997, 63, 1508-1514.	1.1	54
964	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. <i>Blood</i> , 1997, 90, 1558-1564.	1.4	8
965	A Putative Role of NO and Oxidant Injury in the Pathogenesis of Hemolytic Uremic Syndrome. , 1997, , 418-427.		0
966	Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies. <i>American Journal of Kidney Diseases</i> , 1996, 27, 34-41.	2.0	52
967	Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. <i>American Journal of Kidney Diseases</i> , 1996, 28, 23-31.	2.0	28
968	Malignant vascular disease of the kidney: Nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. <i>American Journal of Kidney Diseases</i> , 1996, 27, 459-475.	2.0	57
969	Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. <i>American Journal of Kidney Diseases</i> , 1996, 27, 416-423.	2.0	99
970	Increased nitric oxide formation in recurrent thrombotic microangiopathies: A possible mediator of microvascular injury. <i>American Journal of Kidney Diseases</i> , 1996, 27, 790-796.	2.0	50
971	The role of vasoactive molecules of endothelial origin in the pathophysiology of normal pregnancy and pregnancy-induced hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 1996, 5, 347-352.	2.1	8
972	Role of Endothelin in the Development of Glomerulosclerosis. <i>Kidney and Blood Pressure Research</i> , 1996, 19, 182-183.	2.0	13

#	ARTICLE	IF	CITATIONS
973	Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: New antirejection drugs. Expert Opinion on Therapeutic Patents, 1996, 6, 871-891.	5.2	4
974	Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study. Diabetologia, 1996, 39, 1625-1628.	6.6	44
975	Cyclosporine induces glomerulosclerosis: Three-dimensional definition of the lesions in a rat model of renal transplant. Kidney International, 1996, 49, 1283-1288.	5.6	34
976	Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney International, 1996, 49, 282-286.	5.6	47
977	Acceleration of Recovery in Acute Renal Failure: From Cellular Mechanisms of Tubular Repair to Innovative Targeted Therapies. Renal Failure, 1996, 18, 377-388.	2.0	22
978	Heparin-induced thrombocytopenia-background and implications for haemodialysis. Nephrology Dialysis Transplantation, 1996, 11, 2120-2122.	0.8	15
979	The pathophysiology and management of thrombotic thrombocytopenic purpura. European Journal of Haematology, 1996, 56, 191-207.	2.3	108
980	CTLA4Ig ALONE OR IN COMBINATION WITH LOW-DOSE CYCLOSPORINE FAILS TO REVERSE ACUTE REJECTION OF RENAL ALLOGRAFT IN THE RAT. Transplantation, 1996, 61, 1320-1322.	1.1	12
981	RECOVERY OF BLOOD MONONUCLEAR CELL CALCINEURIN ACTIVITY SEGREGATES TWO POPULATIONS OF RENAL TRANSPLANT PATIENTS WITH DIFFERENT SENSITIVITIES TO CYCLOSPORINE INHIBITION. Transplantation, 1996, 61, 1526-1531.	1.1	22
982	Thrombogenesis and Anticoagulation in Patients Undergoing Chronic Hemodialysis. , 1996, , 323-332.		0
983	Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Current Opinion in Nephrology and Hypertension, 1995, 4, 339-342.	2.1	71
984	Role of platelets in progressive glomerular diseases. Pediatric Nephrology, 1995, 9, 495-502.	1.8	35
985	Direct podocyte damage in the single nephron leads to albuminuria in vivo. Kidney International, 1995, 47, 1078-1086.	5.6	43
986	ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. Kidney International, 1995, 47, 1319-1326.	5.6	29
987	The hemolytic uremic syndrome. Kidney International, 1995, 48, 2-19.	5.6	183
988	Three-dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. Kidney International, 1995, 48, 155-162.	5.6	59
989	Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4Ig. Kidney International, 1995, 47, 241-246.	5.6	30
990	Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. Blood, 1995, 85, 1696-1703.	1.4	191

#	ARTICLE	IF	CITATIONS
991	Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. <i>Blood</i> , 1995, 86, 4553-4558.	1.4	93
992	Innovative strategies for pharmacological intervention in immune damage to the kidney. <i>Nephrology Dialysis Transplantation</i> , 1995, 10, 1131-1136.	0.8	3
993	PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress. <i>American Journal of Physiology - Cell Physiology</i> , 1995, 269, C42-C47.	4.7	48
994	The Girl with the Curl. <i>New England Journal of Medicine</i> , 1995, 333, 928-931.	30.7	3
995	Î±1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. <i>Lancet, The</i> , 1995, 345, 224-225.	12.2	22
996	Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. <i>American Journal of Kidney Diseases</i> , 1995, 26, 934-941.	2.0	233
997	New insights into circulating cell-endothelium interactions and their significance for glomerular pathophysiology. <i>American Journal of Kidney Diseases</i> , 1995, 26, 541-548.	2.0	26
998	Nitric Oxide Synthesis by Cultured Endothelial Cells Is Modulated by Flow Conditions. <i>Circulation Research</i> , 1995, 76, 536-543.	6.5	444
999	Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. <i>American Journal of Physiology - Renal Physiology</i> , 1994, 267, F1034-F1044.	3.0	9
1000	Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides.. <i>Journal of Experimental Medicine</i> , 1994, 180, 1967-1972.	8.8	37
1001	Inflammation and glomerular injury. <i>Seminars in Immunopathology</i> , 1994, 16, 39-51.	4.1	4
1002	Glomerular perm-selective function. <i>Kidney International</i> , 1994, 45, 398-402.	5.6	27
1003	The role of eicosanoids in the pathogenesis of hemolytic uremic syndrome. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1994, 51, 75-79.	2.3	4
1004	Kidney/pancreas transplantation. <i>Lancet, The</i> , 1994, 343, 971-972.	12.2	0
1005	Pancreas and kidney/pancreas transplants: experimental medicine or real improvement?. <i>Lancet, The</i> , 1994, 343, 27-31.	12.2	79
1006	Long-Term Treatment With Either Enalapril or Nitrendipine Stabilizes Albuminuria and Increases Glomerular Filtration Rate in Non- Insulin-Dependent Diabetic Patients. <i>American Journal of Kidney Diseases</i> , 1994, 24, 753-761.	2.0	62
1007	Following an Initial Decline, Glomerular Filtration Rate Stabilizes in Heart Transplant Patients on Chronic Cyclosporine. <i>American Journal of Kidney Diseases</i> , 1994, 24, 549-553.	2.0	32
1008	Treatment of idiopathic membranous glomerulopathy. <i>Current Opinion in Nephrology and Hypertension</i> , 1994, 3, 155-163.	2.1	7

#	ARTICLE	IF	CITATIONS
1009	MECHANISMS OF ACQUIRED THYMIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. <i>Transplantation</i> , 1994, 58, 125-132.	1.1	125
1010	Low-dose aspirin and bleeding in uremia. <i>American Journal of Hematology</i> , 1993, 42, 235-236.	4.3	5
1011	Glucose-induced changes in renal haemodynamics in proteinuric Type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicylic acid infusion. <i>Diabetologia</i> , 1993, 36, 622-627.	6.6	22
1012	Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. <i>Kidney International</i> , 1993, 43, 706-711.	5.6	189
1013	Methylprednisolone normalizes superoxide anion production by polymorphs from patients with ANCA-positive vasculitides. <i>Kidney International</i> , 1993, 44, 215-220.	5.6	30
1014	Failure to predict cyclosporine area under the curve using a limited sampling strategy. <i>Kidney International</i> , 1993, 44, 436-439.	5.6	21
1015	A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. <i>Kidney International</i> , 1993, 44, 440-444.	5.6	216
1016	Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. <i>Kidney International</i> , 1993, 44, 445-450.	5.6	205
1017	Defective glomerular [³ H]lysoPAF metabolism in the autologous phase of rabbit nephrotic nephritis. <i>Kidney International</i> , 1993, 44, 747-754.	5.6	1
1018	Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. <i>Kidney International</i> , 1993, 43, 354-358.	5.6	153
1019	Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. <i>Kidney International</i> , 1993, 43, 426-429.	5.6	22
1020	Thrombotic Thrombocytopenic Purpura: Evidence That Infusion Rather Than Removal of Plasma Induces Remission of the Disease. <i>American Journal of Kidney Diseases</i> , 1993, 21, 314-318.	2.0	74
1021	Reversible Activation Defect of the Platelet Glycoprotein IIb-IIIa Complex in Patients With Uremia. <i>American Journal of Kidney Diseases</i> , 1993, 22, 668-676.	2.0	93
1022	Plasma Exchange in Children With Hemolytic-Uremic Syndrome at Risk of Poor Outcome. <i>American Journal of Kidney Diseases</i> , 1993, 22, 264-266.	2.0	49
1023	Edema of the Nephrotic Syndrome: The Role of the Atrial Peptide System. <i>American Journal of Kidney Diseases</i> , 1993, 22, 355-366.	2.0	38
1024	Prevalence and Significance of Hypertension in Systemic Lupus Erythematosus. <i>American Journal of Kidney Diseases</i> , 1993, 21, 58-60.	2.0	9
1025	Endothelins in the control of cardiovascular and renal function. <i>Lancet</i> , The, 1993, 342, 589-593.	12.2	110
1026	Idiopathic membranous nephropathy. <i>Lancet</i> , The, 1993, 342, 1277-1280.	12.2	8

#	ARTICLE	IF	CITATIONS
1027	Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy. <i>New England Journal of Medicine</i> , 1993, 329, 85-89.	30.7	381
1028	Slowing the Progression of Diabetic Nephropathy. <i>New England Journal of Medicine</i> , 1993, 329, 1496-1497.	30.7	19
1029	Renal Handling of Sodium in the Nephrotic Syndrome. <i>American Journal of Nephrology</i> , 1993, 13, 413-421.	3.2	13
1030	THYMIC RECOGNITION OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES INDUCES DONOR-SPECIFIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. <i>Transplantation</i> , 1993, 56, 461-465.	1.1	135
1031	Reduced Fibrinolytic Activity in Glomeruli Isolated from Rabbits Infused with Tumor Necrosis Factor. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1993, 23, 173-178.	0.3	1
1032	Interleukin-1 and Glomerular Mesangial Cells. <i>Kidney and Blood Pressure Research</i> , 1993, 16, 89-92.	2.0	3
1033	Interleukin-6 stimulates gene expression of extracellular matrix components in bovine mesangial cells in culture. <i>Mediators of Inflammation</i> , 1993, 2, 429-433.	3.1	3
1034	Supernatant of endothelial cells exposed to laminar flow inhibits mesangial cell proliferation. <i>American Journal of Physiology - Cell Physiology</i> , 1993, 264, C1080-C1083.	4.7	11
1035	Haemolytic Uraemic Syndrome and Thrombotic Thrombocytopenic Purpura. <i>Vascular Medicine Review</i> , 1993, vmr-4, 273-292.	0.2	0
1036	Colchicine allows prolonged survival of highly reactive renal allograft in the rat.. <i>Journal of the American Society of Nephrology: JASN</i> , 1993, 4, 1294-1299.	0.5	12
1037	Atrial Natriuretic Peptide and Prostacyclin Synergistically Mediate Hyperfiltration and Hyperperfusion of Diabetic Rats. <i>Diabetes</i> , 1992, 41, 533-538.	0.9	49
1038	EVIDENCE OF THE CENTRAL ROLE OF THE THYMUS IN THE INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO A RENAL ALLOGRAFT. <i>Transplantation</i> , 1992, 54, 943-944.	1.1	14
1039	THE ACUTE EFFECT OF FK506 AND CYCLOSPORINE ON ENDOTHELIAL CELL FUNCTION AND RENAL VASCULAR RESISTANCE. <i>Transplantation</i> , 1992, 54, 775-779.	1.1	84
1040	DAILY RENAL HYPOPERFUSION INDUCED BY CYCLOSPORINE IN PATIENTS WITH RENAL TRANSPLANTATION. <i>Transplantation</i> , 1992, 54, 56-60.	1.1	151
1041	Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. <i>Lancet, The</i> , 1992, 339, 1421.	12.2	30
1042	Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. <i>Lancet, The</i> , 1992, 339, 835-836.	12.2	27
1043	Renal Prostacyclin Biosynthesis Is Reduced in Children With Hemolytic-Uremic Syndrome in the Context of Systemic Platelet Activation. <i>American Journal of Kidney Diseases</i> , 1992, 20, 144-149.	2.0	26
1044	Defective Platelet Aggregation in Response to Platelet-Activating Factor in Uremia Associated With Low Platelet Thromboxane A2 Generation. <i>American Journal of Kidney Diseases</i> , 1992, 19, 318-325.	2.0	21

#	ARTICLE	IF	CITATIONS
1045	Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. American Journal of Medicine, 1992, 92, S60-S63.	1.4	31
1046	Turnour necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells. Mediators of Inflammation, 1992, 1, 263-266.	3.1	4
1047	Evidence against a pathogenetic role for endothelin in pre-eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 1992, 99, 798-802.	2.5	57
1048	Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes. Kidney International, 1992, 41, 813-821.	5.6	20
1049	Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. Kidney International, 1992, 41, 1081-1084.	5.6	33
1050	Thromboxane synthesis and action within the kidney. Kidney International, 1992, 41, 1483-1493.	5.6	95
1051	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney International, 1992, 42, 981-990.	5.6	22
1052	Analysis by fast atom bombardment mass spectrometry of phospholipids from tubuli, glomeruli, and urine of normal rats and rats with acute renal failure. Biochemical Medicine and Metabolic Biology, 1992, 48, 219-226.	0.7	1
1053	Aspirin in Hypertension of Pregnancy. , 1992, , 93-105.		0
1054	Increased urinary excretion of platelet activating factor in mice with lupus nephritis. Life Sciences, 1991, 48, 1429-1437.	4.4	17
1055	Induction of unresponsiveness via intrathymic inoculation. Lancet, The, 1991, 338, 450.	12.2	4
1056	Recombinant Human Erythropoietin to Correct Uremic Bleeding. American Journal of Kidney Diseases, 1991, 18, 44-49.	2.0	73
1057	Low-Protein Diet and Glomerular Size-Selective Function in Membranous Glomerulopathy. American Journal of Kidney Diseases, 1991, 17, 317-322.	2.0	15
1058	Prevention and Treatment of Pregnancy-Associated Hypertension: What Have We Learned in the Last 10 Years?. American Journal of Kidney Diseases, 1991, 18, 285-305.	2.0	60
1059	Morphometrical Analysis of Glomerular Changes Induced by Cyclosporine in the Rat. American Journal of Kidney Diseases, 1991, 17, 537-543.	2.0	8
1060	Human placenta expresses endothelin gene and corresponding protein is excreted in urine in increasing amounts during normal pregnancy. American Journal of Obstetrics and Gynecology, 1991, 164, 844-848.	1.4	50
1061	Induction of unresponsiveness via intrathymic inoculation. Lancet, The, 1991, 337, 1487-1488.	12.2	3
1062	Cyclosporine-induced renal dysfunction in experimental animals and humans. Transplantation Reviews, 1991, 5, 63-80.	3.1	23

#	ARTICLE	IF	CITATIONS
1063	Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation. <i>Lancet, The</i> , 1991, 337, 750-752.	12.2	132
1064	Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in rats. <i>American Journal of Physiology - Renal Physiology</i> , 1991, 261, F85-F90.	3.0	7
1065	Increased renal endothelin production in rats with reduced renal mass. <i>American Journal of Physiology - Renal Physiology</i> , 1991, 260, F331-F339.	3.0	66
1066	CO-PARTICIPATION OF THROMBOXANE A2 AND LEUKOTRIENE C4 AND D4 IN MEDIATING CYCLOSPORINE-INDUCED ACUTE RENAL FAILURE. <i>Transplantation</i> , 1991, 52, 873-878.	1.1	22
1067	High-performance liquid chromatographic determination of iothalamic acid in human plasma and urine. <i>Biomedical Applications</i> , 1991, 570, 435-440.	1.7	13
1068	Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. <i>Kidney International</i> , 1991, 39, 1267-1273.	5.6	127
1069	Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. <i>Kidney International</i> , 1991, 40, 243-250.	5.6	105
1070	Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. <i>Kidney International</i> , 1991, 39, 647-652.	5.6	39
1071	Mechanisms and Mediators of Cyclosporine-Induced Renal Vascular Changes. , 1991, , 543-554.		0
1072	Altered Renovascular Endothelial Functions During Nephrotoxicity. , 1991, , 157-166.		0
1073	Oral zeranol shortens the prolonged bleeding time of uremic rats. <i>Kidney International</i> , 1990, 38, 96-100.	5.6	5
1074	Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?. <i>Kidney International</i> , 1990, 38, 384-394.	5.6	347
1075	Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. <i>Kidney International</i> , 1990, 38, 447-458.	5.6	28
1076	Endothelin and eicosanoid synthesis in cultured mesangial cells. <i>Kidney International</i> , 1990, 37, 927-933.	5.6	26
1077	Ticlopidine prevents renal disease progression in rats with reduced renal mass. <i>Kidney International</i> , 1990, 37, 934-942.	5.6	33
1078	Thrombotic Thrombocytopenic Purpura and Related Disorders. <i>Hematology/Oncology Clinics of North America</i> , 1990, 4, 219-241.	1.9	85
1079	Role of Platelet-Activating Factor in Renal Immune Injury and Proteinuria. <i>American Journal of Nephrology</i> , 1990, 10, 98-104.	3.2	16
1080	Glomerular response to hyperglycemia in human diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 1990, 259, F545-F552.	3.0	21

#	ARTICLE	IF	CITATIONS
1081	Hemolytic uremic syndrome associated with verocytotoxin-producing <i>Escherichia coli</i> infection in acquired immunodeficiency syndrome [letter]. <i>Blood</i> , 1990, 75, 2465-2465.	1.4	18
1082	Preliminary report: renal thromboxane A2 synthesis in children with frequent relapsing nephrotic syndrome. <i>Lancet, The</i> , 1990, 336, 533-534.	12.2	11
1083	Role of Insulin and Atrial Natriuretic Peptide in Sodium Retention in Insulin-Treated IDDM Patients During Isotonic Volume Expansion. <i>Diabetes</i> , 1990, 39, 289-298.	0.9	119
1084	Effect of Ticlopidine on the Evolution of Renal Disease in Rats with Reduced Renal Mass. <i>Contributions To Nephrology</i> , 1990, 81, 279-288.	0.0	0
1085	Renal metabolism and urinary excretion of platelet-activating factor in the rat.. <i>Journal of Biological Chemistry</i> , 1990, 265, 19414-19419.	3.5	12
1086	Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat.. <i>Journal of Clinical Investigation</i> , 1990, 85, 541-549.	6.7	231
1087	Role of endothelium-derived nitric oxide in the bleeding tendency of uremia.. <i>Journal of Clinical Investigation</i> , 1990, 86, 1768-1771.	6.7	110
1088	Eicosanoids and Acute Renal Failure. <i>Current Concepts in Critical Care</i> , 1990, , 115-129.	0.0	0
1089	Models of human renal disease. , 1990, , 111-123.		0
1090	Hyperparathyroidism Does Not Influence the Abnormal Primary Haemostasis in Patients with Chronic Renal Failure. <i>Nephrology Dialysis Transplantation</i> , 1989, 4, 971-974.	0.8	8
1091	Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. <i>Blood</i> , 1989, 74, 978-983.	1.4	51
1092	Abnormalities of Arachidonate Metabolism in Experimental Ciclosporin Nephrotoxicity. <i>American Journal of Nephrology</i> , 1989, 9, 72-77.	3.2	8
1093	Sequence of Glomerular Changes in Experimental Endotoxemia: A Possible Model of Hemolytic Uremic Syndrome. <i>Nephron</i> , 1989, 53, 330-337.	1.8	19
1094	Effects of Tertatolol on Renal Function in the Isolated Perfused Rat Kidney. <i>American Journal of Hypertension</i> , 1989, 2, 223S-227S.	2.0	4
1095	Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. <i>American Journal of Hematology</i> , 1989, 31, 32-35.	4.3	59
1096	Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. <i>Kidney International</i> , 1989, 36, 57-64.	5.6	57
1097	Renal Vascular and Thrombotic Effects of Cyclosporine. <i>American Journal of Kidney Diseases</i> , 1989, 13, 261-272.	2.0	189
1098	Angiotensin-Converting Enzyme Inhibition Ameliorates the Defect in Glomerular Size Selectivity in Hyponatremic Hypertensive Syndrome. <i>American Journal of Kidney Diseases</i> , 1989, 14, 170-177.	2.0	22

#	ARTICLE	IF	CITATIONS
1099	Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. <i>Toxicology Letters</i> , 1989, 46, 65-75.	1.3	8
1100	Effect of Low-Dose Aspirin on Fetal and Maternal Generation of Thromboxane by Platelets in Women at Risk for Ppregnancy-Induced Hypertension. <i>New England Journal of Medicine</i> , 1989, 321, 357-362.	30.7	332
1101	Metabolism of thromboxane B2 in the isolated perfused rat kidney: mass spectrometric identification of urinary products. <i>Lipids and Lipid Metabolism</i> , 1989, 1006, 167-172.	2.5	6
1102	Glomerular Hyperfiltration and Urinary Prostaglandins in Type 1 Diabetes Mellitus. <i>Diabetic Medicine</i> , 1989, 6, 219-223.	2.5	31
1103	Eicosanoids and Platelet Activating Factor as Possible Mediators of Injury in Experimental Nephropathies. <i>Advances in Experimental Medicine and Biology</i> , 1989, 259, 221-247.	9.0	8
1104	Development of a mass spectrometric method to quantitate platelet activating factor in mouse urine.. <i>Journal of Lipid Research</i> , 1989, 30, 1977-1981.	4.2	9
1105	Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. <i>Blood</i> , 1989, 74, 978-983.	1.4	59
1106	Catecholamine receptor binding in rat kidney: Effect of aging. <i>Kidney International</i> , 1988, 33, 1073-1077.	5.6	27
1107	Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity. <i>Kidney International</i> , 1988, 34, 164-174.	5.6	69
1108	Sex related differences in glomerular ultrafiltration and proteinuria in Munich-Wistar rats. <i>Kidney International</i> , 1988, 34, 481-486.	5.6	133
1109	Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. <i>Kidney International</i> , 1988, 34, 853-858.	5.6	78
1110	Metabolism of arachidonic acid in isolated glomeruli from pig kidney. <i>Lipids and Lipid Metabolism</i> , 1988, 961, 110-121.	2.5	8
1111	Plasma infusion for hemolytic-uremic syndrome in children: Results of a multicenter controlled trial. <i>Journal of Pediatrics</i> , 1988, 112, 284-290.	2.3	128
1112	BLEEDING IN RENAL FAILURE. <i>Lancet, The</i> , 1988, 331, 1205-1208.	12.2	193
1113	Influence of Antacid Administrations on Aspirin Absorption in Patients With Chronic Renal Failure on Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 1988, 11, 338-342.	2.0	10
1114	Steroids and Cytotoxic Drugs in the Treatment of Membranous Glomerulopathy. <i>Nephron</i> , 1988, 50, 263-264.	1.8	4
1115	What Is the Basis for the Use of Steroids in the Treatment of Idiopathic Membranous Nephropathy?. <i>Nephron</i> , 1987, 45, 1-6.	1.8	10
1116	Are â€œRoutineâ€ Clinical and Laboratory Examinations of Any Help in the Treatment of Chronic Hemodialysis Patients?. <i>American Journal of Kidney Diseases</i> , 1987, 10, 23-27.	2.0	1

#	ARTICLE	IF	CITATIONS
1117	Prostacyclin and Hemolytic Uremic Syndrome: From the Laboratory to An International Registry. <i>International Journal of Artificial Organs</i> , 1987, 10, 337-340.	1.5	1
1118	Glomerular size selectivity in nephrotic rats exposed to diets with different protein content. <i>American Journal of Physiology - Renal Physiology</i> , 1987, 253, F318-F327.	3.0	12
1119	Antibody-mediated extraction/negative-ion chemical ionization mass spectrometric measurement of thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine. <i>Analytical Biochemistry</i> , 1987, 163, 255-262.	2.5	55
1120	Studies by conventional and low denaturing isoelectric focusing on albumin microheterogeneity under normal conditions and in experimental nephrosis. <i>Electrophoresis</i> , 1987, 8, 215-220.	2.8	10
1121	Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. <i>Kidney International</i> , 1987, 31, 1248-1256.	5.6	49
1122	Indomethacin reduces proteinuria in passive Heymann nephritis in rats. <i>Kidney International</i> , 1987, 31, 1335-1343.	5.6	55
1123	HUS and TTP: Variable expression of a single entity. <i>Kidney International</i> , 1987, 32, 292-308.	5.6	236
1124	Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition.. <i>Journal of Clinical Investigation</i> , 1987, 79, 1788-1797.	6.7	97
1125	MODERATE DOSES OF ASPIRIN AND RISK OF BLEEDING IN RENAL FAILURE. <i>Lancet, The</i> , 1986, 327, 414-416.	12.2	67
1126	Adriamycin-Induced Glomerulosclerosis in the Rat. <i>American Journal of Kidney Diseases</i> , 1986, 7, 12-19.	2.0	102
1127	Superimposed Nephritis: A Separate Entity Among Glomerular Diseases?. <i>American Journal of Kidney Diseases</i> , 1986, 7, 205-212.	2.0	28
1128	Pathogenesis of Preeclampsia. , 1986, , 13-33.		5
1129	Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. <i>American Journal of Physiology - Renal Physiology</i> , 1986, 251, F581-F587.	3.0	50
1130	Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. <i>Kidney International</i> , 1986, 30, 488-496.	5.6	158
1131	Recurrent abortion with lupus anticoagulant, and pre-eclampsia: a common final pathway for two different diseases? Case report. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1986, 93, 194-196.	2.5	16
1132	Conjugated Estrogens for the Management of Bleeding Associated with Renal Failure. <i>New England Journal of Medicine</i> , 1986, 315, 731-735.	30.7	217
1133	Renin-Angiotensin System and Glomerular Prostaglandins in Early Nephrotoxicity of Ciclosporin. <i>Contributions To Nephrology</i> , 1986, 51, 120-125.	0.0	4
1134	Low-protein diet prevents glomerular damage in adriamycin-treated rats. <i>Kidney International</i> , 1985, 28, 21-27.	5.6	51

#	ARTICLE	IF	CITATIONS
1135	Inhibition of Human Platelet Aggregation by Parathyroid Hormone. American Journal of Nephrology, 1985, 5, 243-247.	3.2	24
1136	Renal Biopsy in Patients With Acute Renal Failure and Prolonged Bleeding Time: A Preliminary Report. American Journal of Kidney Diseases, 1985, 6, 397-399.	2.0	29
1137	Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis.. Journal of Clinical Investigation, 1985, 75, 94-101.	6.7	149
1138	Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.. Journal of Clinical Investigation, 1985, 76, 1011-1018.	6.7	186
1139	Heparin for Hemodialysis: Practical Guidelines for Administration and Monitoring. International Journal of Artificial Organs, 1984, 7, 269-274.	1.5	11
1140	The Lupus Anticoagulant. Experimental Biology and Medicine, 1984, 176, 337-341.	2.4	10
1141	The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney International, 1984, 25, 671-676.	5.6	36
1142	RENAL BIOPSY IN PATIENTS WITH ACUTE RENAL FAILURE AND PROLONGED BLEEDING TIME. Lancet, The, 1984, 324, 978-979.	12.2	22
1143	Haemolytic Uraemic Syndromes. , 1984, , 276-297.		0
1144	Prostanoid-Related Platelet Abnormalities in Renal Disease. , 1984, , 1406-1411.		0
1145	In vivo platelet activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients. Kidney International, 1983, 23, 506-513.	5.6	17
1146	STAGNATIONS AND REGRESSIONS IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS. Lancet, The, 1983, 322, 90-92.	12.2	4
1147	Effect of Cyclosporin A on prostacyclin synthesis by vascular tissue. Thrombosis Research, 1983, 32, 373-379.	1.7	95
1148	Deamino-8-D-Arginine Vasopressin Shortens the Bleeding Time in Uremia. New England Journal of Medicine, 1983, 308, 8-12.	30.7	625
1149	Reduced Platelet Thromboxane Formation in Uremia. EVIDENCE FOR A FUNCTIONAL CYCLOOXYGENASE DEFECT. Journal of Clinical Investigation, 1983, 71, 762-768.	6.7	153
1150	Platelet and Vascular Prostaglandins in Uremia and Thrombotic Microangiopathy. , 1983, , 319-325.		0
1151	Platelet Prostaglandin Production in the Nephrotic Syndrome. , 1983, , 327-331.		0
1152	URAEMIC BLEEDING: ROLE OF ANAEMIA AND BENEFICIAL EFFECT OF RED CELL TRANSFUSIONS. Lancet, The, 1982, 320, 1013-1015.	12.2	308

#	ARTICLE	IF	CITATIONS
1153	Haemolytic uraemic syndrome: therapeutic effect of plasma infusion.. The BMJ, 1982, 285, 1304-1306.	1.0	65
1154	Platelet and Vascular Prostaglandins in Uraemia, Thrombotic Microangiopathy and Pre-Eclampsia. , 1982, , 209-215.		0
1155	Platelet and vascular prostaglandins in uraemia, thrombotic microangiopathy and pre-eclampsia. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences, 1981, 294, 339-342.	2.3	6
1156	PARATHYROID HORMONE INHIBITS HUMAN PLATELET FUNCTION. Lancet, The, 1981, 318, 1321-1323.	12.2	43
1157	THROMBOTIC TENDENCY IN SYSTEMIC LUPUS ERYTHEMATOSUS. Lancet, The, 1981, 317, 719.	12.2	46
1158	PROSTACYCLIN DEFICIENCY IN THROMBOTIC MICROANGIOPATHY. Lancet, The, 1981, 318, 1422-1423.	12.2	15
1159	Plasmatic regulation of vascular prostacyclin in pregnancy.. British Medical Journal, 1981, 282, 512-514.	0.8	46
1160	Platelets from Uraemic Patients React Normally to Prostacyclin. International Journal of Artificial Organs, 1980, 3, 125-125.	1.5	2
1161	Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients.. Journal of Clinical Pathology, 1980, 33, 631-634.	2.2	7
1162	Prostacyclin and Thrombotic Microangiopathy. Seminars in Thrombosis and Hemostasis, 1980, 6, 391-394.	2.8	40
1163	Aspirin and Thrombosis in Patients Undergoing Hemodialysis. New England Journal of Medicine, 1980, 302, 1420-1421.	30.7	1
1164	Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. Prostaglandins, 1980, 20, 105-110.	1.2	235
1165	PROSTACYCLIN GENERATION BY CULTURED ENDOTHELIAL CELLS IN HÅ†MOLYTIC URÅ†MIC SYNDROME. Lancet, The, 1980, 315, 656-657.	12.2	45
1166	REDUCTION OF FETAL VASCULAR PROSTACYCLIN ACTIVITY IN PRE-ECLAMPSIA. Lancet, The, 1980, 316, 310.	12.2	39
1167	Vascular Prostacyclin and Plasminogen Activator Activity in Experimental and Clinical Conditions of Disturbed Haemostasis or Thrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1979, 8, 300-311.	0.3	2
1168	Plasmapheresis in the treatment of acute renal failure in multiple myeloma. American Journal of Medicine, 1979, 66, 684-688.	1.4	82
1169	Platelet hyperaggregability and the nephrotic syndrome. Thrombosis Research, 1979, 16, 345-354.	1.7	109
1170	Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. Thrombosis Research, 1979, 16, 517-525.	1.7	66

#	ARTICLE	IF	CITATIONS
1171	Prostacyclin and human foetal circulation. Prostaglandins, 1979, 18, 341-348.	1.2	105
1172	ASPHYXIA IN GOODPASTURE'S SYNDROME: EARLY TREATMENT BY IMMUNOSUPPRESSION AND PLASMA EXCHANGE. Lancet, The, 1978, 311, 552.	12.2	4
1173	HqMOLYTIC-URqMIC SYNDROME: DEFICIENCY OF PLASMA FACTOR(S) REGULATING PROSTACYCLIN ACTIVITY?. Lancet, The, 1978, 312, 871-872.	12.2	275
1174	Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. Thrombosis Research, 1978, 13, 531-536.	1.7	66
1175	Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thrombosis Research, 1978, 13, 1007-1015.	1.7	75
1176	Human renal cortex generates prostacyclin-like activity. Thrombosis Research, 1978, 12, 363-366.	1.7	17
1177	Bleeding in Renal Failure: Altered Platelet Function in Chronic Uraemia only Partially Corrected by Haemodialysis. Nephron, 1978, 22, 347-353.	1.8	113
1178	Factor VIII-related protein on vascular intima of patients with chronic renal failure and prolonged bleeding times.. The BMJ, 1978, 1, 70-72.	1.0	9
1179	DOES ASPIRIN PRECIPITATE MAJOR GASTROINTESTINAL BLEEDING IN PATIENTS ON HÃ†MODIALYSIS?. Lancet, The, 1977, 310, 359-360.	12.2	6
1180	ABNORMAL TISSUE REPAIR IN GLANZMANN'S THROMBASTHENIA. Lancet, The, 1977, 309, 374-375.	12.2	13
1181	Skin fibroblasts from a patient with Glanzmann's Thrombasthenia do not induce fibrin clot retraction. Thrombosis Research, 1977, 10, 173-174.	1.7	22
1182	Prostacyclin (PGI2) and bleeding time in uremic patients. Thrombosis Research, 1977, 11, 919-920.	1.7	24
1183	PROSTACYCLIN-LIKE ACTIVITY AND BLEEDING IN RENAL FAILURE. Lancet, The, 1977, 310, 1195-1197.	12.2	98
1184	Bleeding in renal failure: is von Willebrand factor implicated?. The BMJ, 1977, 2, 359-361.	1.0	52
1185	Myasthenia Gravis, Thrombocytopenia and HLA Antigens. Annals of Internal Medicine, 1977, 87, 250.	9.7	15
1186	ADP, Ristocetin, Bovine Factor VIII and Thrombasthenic Platelets. Thrombosis and Haemostasis, 1976, 36, 286-288.	3.5	3
1187	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Thrombus Formation. SSRN Electronic Journal, 0, , .	0.3	1
1188	Reply: Nephrons are generated via a series of committed progenitors. Nature Reviews Nephrology, 0, , .	9.7	0

#	ARTICLE	IF	CITATIONS
1189	Diffusion magnetic resonance imaging for kidney cyst volume quantification and non-cystic tissue characterisation in ADPKD. <i>European Radiology</i> , 0, , .	4.7	2
1190	DEVELOPING THERAPIES FOR C3G: REPORT OF THE KIDNEY HEALTH INITIATIVE C3G TRIAL ENDPOINTS WORK GROUP. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 0, , .	4.6	0
1191	Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 0, , .	9.7	0